

DNL343 is an investigational CNS penetrant eIF2B activator that prevents and reverses the effects of neurodegeneration caused by the Integrated Stress Response

Reviewed Preprint

Published from the original preprint after peer review and assessment by eLife.

About eLife's process

Reviewed preprint posted

November 14, 2023 (this version)

Sent for peer review

September 8, 2023

Posted to bioRxiv

August 22, 2023

Ernie Yulyaningsih , Jung H. Suh, Melania H. Fanok, Roni Chau, Hilda Solanoy, Ryan Takahashi, Anna I. Bakardjiev, Isabel Becerra, N. Butch Benitez, Chi-Lu Chiu, Sonnet S Davis, William E. Dowdle, Timothy Earr, Anthony A. Estrada, Audrey Gill, Connie Ha, Patrick C. G. Haddick, Kirk R. Henne, Martin Larhammar, Amy Wing-Sze Leung, Romeo Maciucă, Bahram Memarzadeh, Hoang N. Nguyen, Alicia Nugent, Maksim Osipov, Yingqing Ran, Kevin Rebadulla, Elysia Roche, Thomas Sandmann, Jing Wang, Joseph W. Lewcock, Kimberly Searce-Levie, Lesley A. Kane, Pascal E. Sanchez

Denali Therapeutics, South San Francisco, USA • Altos Lab, Redwood City, USA • BioArctic, Stockholm, Sweden • Genentech, South San Francisco, USA • Cajal Neuroscience, Seattle, USA

 https://en.wikipedia.org/wiki/Open_access

 Copyright information

Abstract

The integrated stress response (ISR) is a conserved pathway in eukaryotic cells that is activated in response to multiple sources of cellular stress. Although acute activation of this pathway restores cellular homeostasis, intense or prolonged ISR activation perturbs cell function and may contribute to neurodegeneration. DNL343 is an investigational CNS-penetrant small molecule ISR inhibitor designed to activate the eukaryotic initiation factor 2B (eIF2B) and suppress aberrant ISR activation. DNL343 reduced CNS ISR activity and neurodegeneration in a dose-dependent manner in two established *in vivo* models – the optic nerve crush injury and an eIF2B loss of function (LOF) mutant – demonstrating neuroprotection in both and preventing motor dysfunction in the LOF mutant mouse. Treatment with DNL343 at a late stage of disease in the LOF model reversed elevation in plasma biomarkers of neuroinflammation and neurodegeneration and prevented premature mortality. Several proteins and metabolites that are dysregulated in the LOF mouse brains were normalized by DNL343 treatment, and this response is detectable in human biofluids. Several of these biomarkers show differential levels in CSF and plasma from patients with vanishing white matter disease (VWMD), a neurodegenerative disease that is driven by eIF2B LOF and chronic ISR activation, supporting their potential translational relevance. This study demonstrates that DNL343 is a brain penetrant ISR inhibitor capable of attenuating neurodegeneration in mouse models and identifies several biomarker candidates that may be used to assess treatment responses in the clinic.

eLife assessment

This **important** study presents evidence to support the efficacy of oral administration of DNL343, an integrated stress response (ISR) suppressor, in two mouse models in which neurodegeneration is induced. This suggests a therapeutic potential for ISR-related neurodegenerative diseases based on DNL343. The results from the in vivo animal models are **convincing**. However, adequate analyses are needed to fully support the conclusion, as there is no evidence that DNL343 acts in vitro.

Introduction

Eukaryotic initiation factor 2B (eIF2B) is a heterodecameric protein that plays an indispensable role in regulating translation of mRNA into protein. This process is initiated by the assembly of GTP-bound eIF2 and methionine-carrying initiator tRNA (Met-tRNAi) into a ternary complex (TC) which, along with other initiation factors, delivers Met-tRNAi to the AUG start codon. Upon recognition of the start codon, GTP is hydrolyzed, and the resulting eIF2-GDP dissociates from the complex (Gebauer and Hentze 2004 [↗](#), Sonenberg and Hinnebusch 2009 [↗](#)). The continual success of translation initiation is dependent on replenishment of active GTP-bound eIF2 through the exchange of GDP for GTP by eIF2B, a dedicated guanine exchange factor for eIF2 (Bogorad, Lin et al. 2018 [↗](#), Hanson, Hodgson et al. 2022 [↗](#)).

eIF2B activity is dynamically modulated by the integrated stress response (ISR), an evolutionarily conserved signaling pathway that is activated in response to diverse cellular stresses, such as viral infection, amino acid deprivation, protein misfolding, and oxidative stress (Pakos-Zebrucka, Koryga et al. 2016 [↗](#), Costa-Mattioli and Walter 2020 [↗](#)). ISR activation centers on the phosphorylation eIF2B binding partner, eIF2, which led to structural changes that alter its interaction with eIF2B, turning it from a substrate into a competitive inhibitor of the guanine nucleotide exchange factor (GEF) activity of eIF2B (Adomavicius, Guaita et al. 2019 [↗](#), Gordiyenko, Llacer et al. 2019 [↗](#), Kenner, Anand et al. 2019 [↗](#), Schoof, Boone et al. 2021 [↗](#)). As a result, the availability of eIF2-GTP and the subsequent TC become limited, leading to attenuation of global translation. This also gives rise to the paradoxical increase in translation of some stress response proteins (Harding, Novoa et al. 2000 [↗](#)). A common feature of these proteins are upstream open reading frames (uORF) in the 5' region that act as translational decoys to the main protein coding sequence (MCS). Under non-stress conditions these regulatory elements are translated instead of the MCS. However, during ISR activation, when TC and initiation cofactors are limited, translation of these uORFs are bypassed in place of the MCS due to leaky ribosomal scanning (Wethmar, Smink et al. 2010 [↗](#), Young and Wek 2016 [↗](#), Chen and Tarn 2019 [↗](#), Costa-Mattioli and Walter 2020 [↗](#)). One such protein is activating transcription factor 4 (ATF4) (Vattem and Wek 2004 [↗](#)), the primary effector of the ISR which regulates the expression of a wide range of adaptive genes aimed at restoring homeostasis or, in the event that the stress signal cannot be mitigated, triggering apoptosis (Walter and Ron 2011 [↗](#)).

Dysregulation of the ISR pathway has pathological consequences. In human and rodent models, mutations that lead to persistent activation of the ISR are associated with neurological disturbances (Harding, Zhang et al. 2009 [↗](#), Borck, Shin et al. 2012 [↗](#), Abdulkarim, Nicolino et al. 2015 [↗](#), Kernohan, Tetreault et al. 2015 [↗](#), Skopkova, Hennig et al. 2017 [↗](#)) and those that affect the eIF2B subunits cause a rare leukodystrophy called vanishing white matter disease (VWMD) (van der Knaap, Pronk et al. 2006 [↗](#)). Additionally, evidence of constitutive pathway activation has been found in neurodegenerative conditions like Amyotrophic Lateral Sclerosis (ALS) (Ilieva, Ayala et al. 2007 [↗](#), Ito, Yamada et al. 2009 [↗](#)) and Alzheimer's disease (Hoozemans, Veerhuis et al. 2005,

Unterberger, Hoftberger et al. 2006 [\[1\]](#), Hoozemans, van Haastert et al. 2009, Stutzbach, Xie et al. 2013 [\[2\]](#), Storkebaum, Rosenblum et al. 2023 [\[3\]](#)), suggesting that dysregulation of the ISR may contribute to these disorders.

Pharmacological modulation of the ISR is a key area of therapeutic research and has been accomplished through a variety of approaches, including inhibition of upstream ISR kinases, inhibition of eIF2 phosphatases, and activation of eIF2B (Hetz, Axten et al. 2019 [\[4\]](#)). Inhibition of upstream kinases such as PERK has been shown to cause on-target toxicity, which limits their therapeutic potential (Halliday, Radford et al. 2015 [\[5\]](#)). In contrast, eIF2B activators have proven to be well tolerated in animal models while also improving memory and neurological deficits (Sidrauski, Acosta-Alvear et al. 2013 [\[6\]](#), Chou, Krukowski et al. 2017 [\[7\]](#), Abbink, Wisse et al. 2019 [\[8\]](#), Wong, LeBon et al. 2019 [\[9\]](#), Krukowski, Nolan et al. 2020 [\[10\]](#)). The first published eIF2B activator, ISRIB, binds to and stabilizes the eIF2B complex in its decameric form and promotes the GEF activity of eIF2B regardless of the presence of phosphorylated eIF2 (Tsai, Miller-Vedam et al. 2018 [\[11\]](#), Zyryanova, Weis et al. 2018 [\[12\]](#)). ISRIB and its analog, 2BAc, were also neuroprotective in an eIF2B mutant mouse model of VWMD that displays ISR-mediated neurodegeneration (Abbink, Wisse et al. 2019 [\[8\]](#), Wong, LeBon et al. 2019 [\[9\]](#)). Despite this, further development of ISRIB is hampered by its poor solubility and oral bioavailability (Wang, Tan et al. 2018 [\[13\]](#), Abbink, Wisse et al. 2019 [\[8\]](#)), and 2BAc due to its cardiovascular liability (Wong, LeBon et al. 2019 [\[9\]](#)).

DNL343 is an investigational small molecule eIF2B activator that is undergoing clinical development for ALS (NCT05006352, NCT05842941). In immortalized cells and iPSC-derived neurons expressing ALS-linked mutations that are exposed to stressors, DNL343 inhibits the ISR and both prevents and reverses stress granule formation (Sun, Tsai et al. 2023 [\[14\]](#)). The high potency, selectivity, and pharmacokinetic profile of DNL343 across preclinical species make it an ideal tool for studying ISR inhibition *in vivo* (Osipov 2022 [\[15\]](#)).

Here we show that DNL343 reduces ISR activation and neurodegeneration brought on acutely by an optic nerve crush (ONC) injury or chronically by a germline eIF2B LOF mutation in mice. We also show that DNL343 treatment, initiated at a late stage of disease which more accurately replicates a clinical dosing paradigm, reversed these ISR and neurodegeneration biomarkers and prevented premature mortality in the eIF2B LOF mutant. Further, we identified CNS biomarkers of the ISR and neurodegeneration that are measurable in biofluids and showed data that support their translational relevance in samples from patients with VWMD and potentially other indications that are mediated by ISR activation.

Results

DNL343 is a novel brain-penetrant ISR inhibitor

To study the *in vivo* effects of our investigational small molecule eIF2B activator, DNL343 (**Figure 1A** [\[16\]](#)), we first demonstrated its suitability for acute and chronic dosing and evaluated brain exposure in wild-type mice (**Figure 1B** [\[17\]](#)). Following a single dose of DNL343 at 62.5 mg/kg *via* oral gavage, unbound concentrations in the brain were similar to those in plasma (**Figure 1C** [\[18\]](#)), supporting high CNS penetrance in mice (Osipov 2022 [\[15\]](#)). Chronic dosing *via* a non-invasive self-administration route was then examined by formulating DNL343 in mouse chow. After 5 weeks on medicated chow, dose-dependent increases in plasma and brain exposure of DNL343 were observed in mice (**Figure 1D-E** [\[19\]](#)). Plasma DNL343 concentrations were similar following 2 or 29 days of dosing, indicating that steady-state conditions were rapidly achieved and sustained throughout the dosing duration (**Figure 1D** [\[20\]](#)). Further, unbound concentrations of DNL343 in the brain were comparable to those in plasma for all doses at terminal timepoint (**Figure 1E** [\[21\]](#)). No adverse event/s or effects on body weight (**Figure 1F** [\[22\]](#)) were observed during the study, indicating that chronic treatment with DNL343 was well tolerated.




Figure 1

DNL343 is CNS penetrant and suitable for acute and chronic *in vivo* dosing.

(A) Chemical structure of DNL343. (B) Schematic of DNL343 dosing studies in wild-type mice. Left: DNL343 (62.5 mg/kg) was administered *via* oral gavage and mice were taken down 7 hours after. Right: DNL343 was formulated in food at a concentration of 0, 50, 150, or 500 mg/kg chow. Plasma was sampled on days 2 and 29 of dosing at 1h after lights on (zeitgeber, ZT1) and animals were taken down on day 37 at ZT6. (C) DNL343 unbound concentration in the plasma and brain at 7 hours after a single administration of DNL343 at 62.5 mg/kg. (D) DNL343 unbound concentration in the plasma after 2 and 29 days of in-food dosing. (E) DNL343 unbound concentration in the plasma and brain after 37 days of in-food dosing. (F) Body weight of mice maintained on DNL343-formulated diet. Data are presented as mean $\pm$ SEM of N=8/group (C) or N=5/group (D-F).

DNL343 reduced ISR activation and neuronal loss in an optic nerve crush injury model in mice

To determine the impact of DNL343 on ISR dependent neurodegeneration, we first utilized an ONC injury model. This model was selected based on the precedence for ISR activation and reproducible degeneration within a relatively short time period following injury (Larhammar, Huntwork-Rodriguez et al. 2017 [\[4\]](#)). ONC was performed on the left optic nerve of wild-type mice, following which mice were given either vehicle or increasing doses of DNL343 once daily *via* oral gavage. (Figure 2A [\[4\]](#)). The mice were euthanized at 2 or 14 days following the ONC procedure. Unbound concentrations of DNL343 measured in plasma or brain were similar, again confirming CNS penetration (Figure 2B [\[4\]](#)). DNL343 exposure increased in a dose-proportionate manner and demonstrated low variability between animals (Figure 2B [\[4\]](#)). We then measured the expression of ISR-dependent transcripts known to be altered in this model (Larhammar, Huntwork-Rodriguez et al. 2017 [\[4\]](#)) in the retina to confirm DNL343 activity *in vivo*. We found that many of these transcripts were robustly increased in the ipsilateral retina vs undamaged contralateral control retinas at 2 days and, to a lesser extent, 14 days after the ONC (Figure 2C [\[4\]](#)). DNL343 modulated the expression level of these ISR-dependent transcripts in a dose-dependent fashion (Figure 2C [\[4\]](#)) confirming its ability to inhibit ISR *in vivo*. In addition, the highest dose of DNL343 at 12 mg/kg reduced axonal degeneration (Figure 2D [\[4\]](#)) and the two highest doses, 3 and 12 mg/kg, led to significant reduction in retinal ganglion cell (RGC) loss as measured by immunofluorescence analysis of neuronal markers (Figure 2E-F [\[4\]](#)). Together, these data demonstrate pharmacodynamic and neuroprotective effects of DNL343 in an *in vivo* model of acute injury.

eIF2B loss of function causes CNS ISR activation in the mouse

We next sought to develop a model that displays chronic ISR activation in the CNS to further test the effect of DNL343 treatment *in vivo*. To this end, we generated an eIF2B LOF mouse model by knocking in an *Eif2b5* R191H point mutation that is homologous to the VWMD-causing human R195H mutation (Fogli, Wong et al. 2002 [\[4\]](#)). Homozygous knock-in mice will hereafter be referred to as eIF2B HOM. Previous reports of independently generated *Eif2b5* R191H mutant showed ISR overactivation in the CNS and disease phenotypes relevant to human VWMD, such as demyelination and motor function deficit, that ultimately led to premature mortality (Dooves, Bugiani et al. 2016 [\[4\]](#), Abbink, Wisse et al. 2019 [\[4\]](#), Wong, LeBon et al. 2019 [\[4\]](#)). In line with this, characterization of select transcript markers in our eIF2B HOM model at 13-19 weeks of age confirmed ISR activation in the brain of mice homozygous for the mutation, but not in heterozygous or wild-type littermates (Supplemental Figure 1A [\[4\]](#)). The robust elevation of ISR markers were further confirmed in a bulk brain RNA sequencing analysis of a separate cohort of homozygous mutant and wild-type littermates. Known ISR markers rank highly among the 492 protein-coding genes that showed significant differences between eIF2B HOM and wild-type animals (FDR <5%, Supplemental Figure 1B [\[4\]](#), Supplemental Table 1). Genes reported as upregulated due to eIF2B loss of function (Wong, LeBon et al. 2019 [\[4\]](#)) were significantly enriched (gene set enrichment p-value <10⁻²⁰).

ISR activation appears to be most prominent in the CNS since tissues such as peripheral blood mononuclear cells (PBMC) or spleen have no marked upregulation of the ISR markers in homozygous mice relative to wild-type controls (Supplemental Figure 1C [\[4\]](#) and D [\[4\]](#)). This is consistent with the reported CNS and peripheral phenotypes of independently generated models (Dooves, Bugiani et al. 2016 [\[4\]](#), Abbink, Wisse et al. 2019 [\[4\]](#), Wong, LeBon et al. 2019 [\[4\]](#)).




Figure 2

DNL343 engages the ISR and is neuroprotective in an acute ISR-driven neurodegeneration model, the optic nerve crush (ONC).

(A) Schematic of the DNL343 dosing study in the ONC model. Wild-type mice underwent ONC procedure and received once daily DNL343 administrations *via* oral gavage 3 hours later. Animals were taken down at 2 or 14 days after the ONC procedure and retinas, ipsi- and contra-lateral to the crushed site, were collected. (B) DNL343 unbound concentration in the plasma and brain. (C) Heatmap showing expression level of ISR mRNA markers in the retina, ipsilateral to the crush at 2 and 14 days after ONC, relative to control retinas from the uncrushed side. (D-E) DNL343 reduced axonal degeneration score and retinal ganglion cell loss. (F) Representative immunofluorescent images of retinal ganglion cells as identified by TUJ1 (green) and γ-synuclein (red) immunoreactivity. Data are presented as mean ± SEM of N=8-12/group. Statistical significance for DNL343 effect was set at $P < 0.05$ as determined by a one-way ANOVA followed by multiple comparison tests against crushed retina from vehicle-treated animals (*, $P < 0.05$. **, $P < 0.01$, ***, $P < 0.001$, ****, $P < 0.0001$).

Proteomic analysis reveals distinct brain & CSF signatures of ISR activation and neurodegeneration in eIF2B mutant mice

To further characterize the consequences of eIF2B LOF mutation in the mouse brain, we performed bulk brain proteomic characterization on an independent cohort of 11-15-week-old mice. Out of the 7,939 proteins detected, we found 96 proteins that showed significant alteration in the eIF2B HOM genotype relative to wild-type controls (**Figure 3A**). Of these, 45 proteins were also dysregulated on a transcriptional level (**Supplemental Figure 1 B**) suggesting some overlap between the transcriptomic and proteomic changes. In keeping with this, proteins that are regulated by ATF4, a transcription factor the levels of which are known to be ISR-dependent (Pakos-Zebrucka, Koryga et al. 2016), are among those that are most significantly elevated, such as solute carrier (SLC) membrane transport proteins (SLC3A2, SLC7A1, SLC7A1), cystathionine γ -lyase (CTH) and phosphoserine aminotransferase 1 (PSAT1) (**Figure 3A**). Results from the proteomic analysis also show that disturbances in metabolic pathways appear to be the main consequences of the eIF2B LOF mutation on the brain proteome. Indeed, pathways related to metabolism and transport appear to dominate the 5 of the most significantly (adjusted $P < 0.05$) dysregulated protein sets identified in the fast pre-rank protein set enrichment analysis (FPSEA) (**Figure 3B**). This is further supported by our unsupervised principal component analysis which shows that the top proteins contributing to genotype separation are those that are involved in lipid, amino acid, and 1-carbon metabolism (ACSS1, PSAT1, PHGDH, SLC3A2, SHMT2, SLC7A1, ALDH18A1) (**Figure 3C**, dim2). Taken together, these results show that eIF2B LOF leads to gross cerebral metabolic derangement that may contribute to the neurodegenerative phenotype associated with this model.

To understand how the ISR-dependent changes in brain proteins correlate to more clinically translatable fluid biomarkers, we also interrogated the CSF proteome of these eIF2B HOM mice. CSF tandem mass tag (TMT) proteomic analysis identified a total of 572 unique proteins, 472 of which were detected in both CSF and the brain. In contrast to the brain, variances in CSF proteins were insufficient to clearly discriminate eIF2B HOM from wild-type mice by PCA analysis (**Figure 3F**). Reflecting this poorer resolution, univariate analysis identified a total of 58 proteins that were changed with unadjusted $P < 0.05$ (**Figure 3D**). Notably, the protein with the largest fold decrease in the eIF2B HOM CSF was MUP17 ($\log_2$ fold change (FC): -1.3, adjusted $P < 0.05$), a major urinary protein (MUP) and a member of the broader lipocalin protein family, which has been shown to be decreased by ER stress (Weber, Yang et al. 2022). Several proteins associated with microglial activation (CSF1R, LYSZ, and SIRPA) and matrisome remodeling (COL3A1, ITGLB1, CLSTN1) were also higher in homozygous mice relative to wild-type controls (**Figure 3D**). To further examine subtle pathway moderations in the CSF proteome, fast pre-ranked protein set enrichment (FPSEA) analysis was performed. The results showed a highly significant increase in proteins related to the mitochondrial TCA cycle and respiratory electron transport and decreases in proteins associated with cell cycle (**Figure 3E**). While their magnitude of changes were modest, alterations in CSF levels of proteins associated with microglial activation and matrisome remodeling may indicate elevations in inflammatory burden associated with demyelination and neurodegeneration phenotypes seen in humans and other mouse models with mutations in the eIF2B protein (Bugiani, Vuong et al. 2018, Abbink, Wisse et al. 2019, Wong, LeBon et al. 2019). Taken together, our data show very different proteome changes in the brain and CSF from eIF2B HOM mice and collectively, these data point to the CSF proteome representing biomarkers of demyelination and inflammation in the model while the changes in the brain appear to more directly represent cellular ISR dysregulation.




Figure 3

Bulk brain and CSF proteomics reveal distinct signatures of CNS ISR activation and neurodegeneration in the eIF2B HOM mice.

(A) Volcano plot showing protein expression changes in the brain of 11-15-week-old eIF2B HOM mice relative to wild-type control with absolute log₂ fold change (FC) >0.5 and P <0.00005. Blue and red circles denote either down- or up-regulated proteins, respectively. Larger symbols denote proteins with absolute log₂ FC >1. In this analysis, 7,939 proteins were detected. (B) Fast pre-ranked protein set enrichment (FPSEA) analysis of dysregulated proteins matched to mouse reactome pathways. Detected proteins corresponded to 657 pathways defined in the mouse reactome pathways and significantly (adjusted P <0.05) up or down-regulated protein/gene sets are shown. The x-axis in the barcode plot shows ranked lists of proteins and the vertical bar shows protein normalized enrichment scores (NES). Proteins were ranked based on differential expression significance and fold change with most significantly up- or down-regulated genes are shown in the top or the bottom of list, respectively. NES scores indicate overall normalized enrichment scores of the whole set. Significance of enrichments are listed in the adjusted p-value column. (C) Unsupervised principal component analysis results from the brain are shown. Top 10 variables contributing Dim1 and Dim2 are shown in bar plots. Results show a clear separation of eIF2B HOM from wild-type mice along the y axis showing PC2 (Dim2) scores. Top 10 proteins contributing to Dim2 scores were metabolic enzymes involved in lipid, 1-carbon, aldehyde and serine metabolism. (D) Volcano plot showing protein expression changes in the CSF of 11-15-week-old eIF2B HOM mice relative to wild-type. Blue and red circles denote either down- or up-regulated proteins, respectively. Significantly dysregulated proteins with absolute log₂ FC >0.25 and P <0.05 are labelled. 572 proteins were detected in this analysis. (E) Top 3 up- or down-regulated reactome pathways from CSF proteomic analysis identified from FPSEA analysis are shown. A higher abundance of proteins involved in mitochondria, lipid, and carbohydrate metabolism were observed in the eIF2B HOM relative to wild-type mice. Significant downregulations of proteins involved in cell cycle regulation were observed in the CSF compartment. (F) Visualization of unsupervised PCA analysis from CSF proteome data. As compared to the brain proteome, less discrimination between the two genotypes were observed. Between group variances were mostly along the PC1 (Dim1) axis. Top 10 loading variables that contributed to DIM 1 scores were of cytosolic proteins in heat shock, tyrosine, methylation, and extracellular matrix remodeling pathways. Statistical significance was set at P <0.05 as determined by robust linear model. N=7/group.

DNL343 reduced brain ISR activation and prevented disease phenotypes in eIF2B HOM mice

Having characterized the eIF2B HOM model, we next tested the ability of DNL343 to inhibit ISR activation in these mice by initiating treatment at 10-17 weeks of age, before disease onset (**Figure 4A**) (based on clinical signs & plasma biomarker of neurodegeneration (**Figure 4F**)). Animals received DNL343 medicated chow and intake was steady across all groups, achieving levels equivalent to oral gavage doses of 0, 0.3, 1, 3, or 10 mg/kg (**Supplemental Figure 2A-C**). DNL343 exposure in the plasma showed a stable and dose-dependent profile from treatment weeks 2-12 (**Figure 4B**), with similar dose-matched exposure levels between wild-type and eIF2B HOM mice suggesting that DNL343 absorption was not altered in this model (**Figure 4B-C**). After 13 weeks of dosing, DNL343 exposure in the plasma and brain showed a dose-dependent increase (**Figure 4C**) that was accompanied by a dose-dependent reduction of ISR transcript markers in the brain of eIF2B HOM mice (**Figure 4D**). These data further support the notion that DNL343 is effective at blocking chronic CNS ISR activation *in vivo*.

Consistent with the characterization of previously published eIF2B mutant models (Abbink, Wisse et al. 2019, Wong, LeBon et al. 2019), eIF2B HOM animals gain less weight over time compared to their wild-type counterparts. The two highest doses of DNL343 (3 and 10 mg/kg) significantly improved body weight increase (**Figure 4E**), despite a modest reduction in food intake in these groups (**Supplemental Figure 2B**). This improved disease phenotype was mirrored by a similar dose-dependent prevention of plasma NfL elevation, suggesting that DNL343 is neuroprotective in the model (**Figure 4F**). Indeed, following 12 weeks of dosing, eIF2B HOM mice also showed a dose-dependent improvement in motor function as assessed by a balance beam test (**Figure 4G-I**). eIF2B HOM mice treated with DNL343 at doses of 3 and 10 mg/kg were indistinguishable from wild-type controls in the time taken to successfully cross the beam, the numbers of errors measured by foot slips, and falls from the elevated beam (**Figures 4G-I**).

DNL343 normalized proteins and metabolites in the brain and CSF of eIF2B HOM mice

We next evaluated the effect of chronic DNL343 treatment on the proteomic and metabolomic alterations in eIF2B HOM brains and CSF. The baseline genotype-associated differences observed in the brain and CSF proteomes were largely replicated in this older cohort of animals (5–7 month of age, **Supplemental Figure 3 A-B**, **Figure 3A and C**). In addition, targeted metabolomic and lipidomic analyses in the brain revealed profound increases in levels of oxysterols, such as 7-ketocholesterol, and cholesterol esters (CE) in eIF2B HOM mice (**Supplemental Figure 3C**). These lipids tend to be increased in conditions of rapid demyelination (Nugent, Lin et al. 2020), consistent with the implication of the proteomics data and the phenotypes observed in VWMD patients (Schiffmann, Moller et al. 1994, Bugiani, Vuong et al. 2018).

A 13-week treatment with DNL343 with doses that ranged from 0.3 to 10 mg/kg showed significant ($P < 0.05$) dose-dependent normalization of proteins that were downregulated in brains of eIF2B HOM mice (**Figure 5A**, **top cluster**). These included APOE, SLC7A10, CD63, TST and ETNPPL that are associated with cholesterol, exosome, amino acid transport, detoxification and glycerophospholipid metabolism. Chronic treatment also lowered key ISR proteins that were significantly upregulated in eIF2B HOM brains, including proteins involved in serine/glycine/1-carbon metabolism (PSAT1, ALDH1L2, CTH) and alanine/glutamine/leucine transporters (SLC3A2, SLC7A11, SLC7A3) (**Figure 5A**, **bottom cluster**). Further, we identified proteins of amino acid metabolism pathway to be most significantly enriched in DNL343-vs vehicle-treated eIF2B HOM mice (**Figure 5B**). CSF proteomic analysis also showed a clear DNL343 dose-dependent correction of protein biomarkers of microglial activation such as CSF1R, HEXB, CTSS, LY2Z, and CTSB (**Figure 5C**). As predicted by these results, the pathway most impacted by DNL343 treatment was identified to be those that were associated with immune system responses (**Figure**




Figure 4

Chronic DNL343 dosing inhibits ISR overactivation in the brain, restores normal body weight, and prevents functional decline and neurodegeneration in the eIF2B mouse.

(A) Schematic of the prophylactic DNL343 dosing study in the eIF2B HOM mouse model. DNL343 treatment was initiated in pre-symptomatic animals at 10-17 weeks of age. Mice self-administered DNL343-formulated rodent chow to achieve levels equivalent to oral gavage doses of 0, 0.3, 1, 3 or 10 mg/kg. (B) Plasma DNL343 exposure measured biweekly from week 2-12 of dosing. (C) Terminal plasma and brain DNL343 exposure after 13 weeks of dosing. (D) Heatmap visualization of select brain ISR transcript markers in vehicle- and DNL343-treated wild-type and eIF2B HOM mice relative to vehicle-treated wild-type controls. (E) Body weight gain measured weekly. (F) Plasma NfL levels assessed at baseline and throughout the study duration. B and T indicate baseline and terminal timepoints, respectively. (G) The balance beam test was performed after 12 weeks of dosing and the time to cross the beam out of 30 seconds were recorded. (H-I) The number of hindfoot slips and falls during the balance beam test. Data are presented as mean $\pm$ SEM of N=9-18 mice per group. Statistical significance for DNL343 effect was set at $P < 0.05$ as determined by a mixed-effect analysis followed by multiple comparison tests against vehicle-dosed animals of the same genotype at matching timepoints (E-F) or one-way ANOVA followed by multiple comparison tests against vehicle-dosed animals of the same genotype (G-I). (*, $P < 0.05$. **, $P < 0.01$, ***, $P < 0.001$, ****, $P < 0.0001$).

5D [↗](#)). As increased abundance of these proteins in the CSF have been associated with higher microglia activation, their correction by DNL343 may reflect downregulation of inflammation observed in the mutant mice. Furthermore, significant increases in 7-ketocholesterol and CE accumulation observed in eIF2B HOM mice were also dose-dependently corrected by chronic DNL343 treatment (**Figure 5E** [↗](#)). Together these omics studies revealed that DNL343 can robustly correct biomarkers of ISR activation in the brain and markers of gliosis and demyelination in the CSF of eIF2B HOM mice at doses ≥ 3 mg/kg.

Potential translational biomarkers are elevated in both eIF2B HOM mice and VWMD patient biofluids

Given the robust changes we observed in brain ISR and CSF inflammation proteins in eIF2B HOM mice, a select number of ISR and neuroinflammatory markers were chosen for evaluation in human samples. Our selection included growth differentiation factor 15 (GDF-15), an ISR-regulated cytokine and biomarker of clinical inflammation and metabolic distress ([Lockhart, Saudek et al. 2020](#) [↗](#), [McGrath, Himali et al. 2020](#) [↗](#)), glial fibrillary acidic protein (GFAP), a marker of reactive astrocytes and an emerging blood biomarker associated with neurodegeneration ([Abdelhak, Foschi et al. 2022](#) [↗](#)), tissue inhibitor of metalloprotease 1 (TIMP-1), an astrocyte-released cytokine that has been implicated in neurodegenerative conditions ([Lorenz, Albers et al. 2003](#) [↗](#)), and monocyte chemoattractant protein (MCP-1). To assess the potential of these biomarkers for clinical translation, we leveraged plasma and CSF samples from patients with VWMD (**Supplemental Table 2**), a neurodegenerative disease that is driven by eIF2B mutations and chronic ISR overactivation ([van der Knaap, Bonkowsky et al. 2022](#) [↗](#)), in addition to samples from DNL343-treated eIF2B HOM mice.

Both mRNA and protein levels of GDF-15 were increased in the eIF2B HOM brains relative to wild-type controls and were dose-dependently reduced by DNL343 treatment (**Figure 6A and B** [↗](#)). These changes were replicated in a separate cohort of animals (**Supplemental Figure 4A** [↗](#) and **B** [↗](#)) and were also detected in the mouse CSF (**Supplemental Figure 4C** [↗](#)) suggesting that detection of this biomarker in the fluid could be a potential surrogate to assess CNS ISR activation and modulation. GDF-15 protein levels were also elevated in the CSF and plasma of VWMD patients relative to healthy controls (**Figure 6C and D** [↗](#)) despite the age dependent increase in this biomarker ([Lockhart, Saudek et al. 2020](#) [↗](#)) that is particularly apparent in the plasma of patients for which longitudinal samples were available (**Supplemental Figure 5A** [↗](#)). The astrocyte activation marker GFAP was elevated in eIF2B HOM mice with levels of mRNA in the brain and protein in the plasma both being corrected by DNL343 treatment (**Figure 6E and F** [↗](#)). In line with these data in the preclinical disease model, GFAP protein concentrations were higher in the CSF and plasma from VWMD patients relative to controls (**Figure 6G and H** [↗](#)). Although both TIMP-1 and MCP-1 levels were elevated in the eIF2B HOM mice, TIMP-1 levels were not altered in VWMD patients relative to controls in either the CSF or plasma and MCP-1 protein was only elevated in VWMD patient plasma (**Figure 6I-P** [↗](#)). Additionally, levels of other potential neurodegeneration biomarkers, interleukin 18 (IL-18) and soluble triggering receptor expressed on myeloid cells 2 (sTREM2), did not diverge in VWMD patients relative to controls (**Supplemental Figure 5B** [↗](#) and **C** [↗](#)). On the other hand, NfL, a marker of neurodegeneration ([Gaetani, Blennow et al. 2019](#) [↗](#)), was significantly elevated in the plasma and CSF of VWMD patients (**Figure 6Q-S** [↗](#) and **Supplemental Figure 5D-E** [↗](#)) mirroring the changes seen in the eIF2B HOM mice (**Figure 4F** [↗](#)).




Figure 5

DNL343 dose-dependently normalized bulk brain and CSF protein and brain metabolite changes associated with ISR activation in the eIF2B HOM mouse.

(A) Heatmap visualization of differential expression of proteins in eIF2B HOM mice vs wild-type controls following treatment with vehicle or DNL343 for 13 weeks (N=3/group). Wild-type mice received vehicle or DNL343 at the 3 mg/kg dose level. Features with significant ($P < 0.05$) dose responses were selected and clustered based on Euclidean distances. Results show two main clusters of responsive protein that were up-(top) or down-regulated (bottom) in a dose-dependent manner. (B) Single enrichment plot of pathway proteins that were most significantly enriched in DNL343-treated eIF2B HOM mice vs vehicle-treated eIF2B HOM mice. Ranks are created based on both the magnitude of change in expression and their significance. Proteins that are upregulated are towards lower ranks whereas those that are downregulated have higher ranks towards the right. Vertical bars indicate locations of each protein hit. (C) CSF proteomic shifts in the same mice shown in panel A are shown. Results show that significant elevation in abundance of CSF markers of microglial activation was decreased with DNL343 treatment at dose higher than 3 mg/kg body weight for two weeks. (D) Single enrichment plot of pathway proteins that were most significantly enriched in DNL343-treated eIF2B HOM mice vs vehicle-treated eIF2B HOM mice. Ranks are created based on both the magnitude of change in expression and their significance. Proteins that are upregulated are towards lower ranks whereas those that are downregulated have higher ranks towards the right. Vertical bars indicate locations of each protein hit. (E) Heatmap visualization of metabolomic changes in the bulk brain of eIF2B HOM relative to wild-type mice. Statistical significance was set at $P < 0.05$ as determined by robust linear model. N=5-10/group.




Figure 6

Exploratory biomarkers responsive to DNL343 in eIF2B mouse model and assessed in VWMD patient CSF and plasma

(A-B) Expression of *Gdf15* mRNA and GDF-15 protein in the brain of eIF2B HOM or wild-type mice treated with DNL343 or vehicle. (C-D) GDF-15 protein levels in the CSF and plasma of VWMD patients and healthy controls (E-F) Expression of brain *Gfap* mRNA and plasma GFAP protein in eIF2B HOM or wild-type mice treated with DNL343 or vehicle. (G-H) GFAP protein levels in the CSF and plasma of VWMD patients and healthy controls. (I-J) TIMP-1 protein levels in the brain and CSF of eIF2B HOM or wild-type mice treated with DNL343 or vehicle. (K-L) TIMP-1 protein levels in the CSF and plasma of VWMD patients and healthy controls (M-N) Expression of the *Ccl2* transcript, which encodes the MCP-1 protein, and levels of MCP-1 protein in the brain of eIF2B HOM or wild-type mice treated with DNL343 or vehicle. (O-P) MCP-1 protein levels in the CSF and plasma of VWMD patients and healthy controls. (Q-R) NfL protein levels in the CSF and plasma of VWMD patients and healthy controls. (S) Heatmap visualization of relative changes in NfL, GDF-15, GFAP and MCP-1 in the CSF of VWMD patients versus healthy controls, presented in log₂ scale. VWMD patient ID#s correspond across [Figure 6S](#) (CSF) and [Supplemental Figure 5E](#) (plasma). Statistical significance was set at $P < 0.05$. For all animal model panels, DNL343 dose is indicated on the x-axis and data is presented as mean $\pm$ SEM of $N = 9-18$ mice per group. Statistical significance for DNL343 effect in the mouse model was determined by a one-way ANOVA followed by multiple comparison tests against vehicle-dosed animals of the same genotype (*, $P < 0.05$. **, $P < 0.01$, ***, $P < 0.001$, ****, $P < 0.0001$). Data from VWMD patients and healthy controls is presented as mean $\pm$ SEM. Statistical significance for the difference between samples from VWMD patients and healthy controls was assessed on log₂ fold change data using Welch's t test (*, $P < 0.05$. **, $P < 0.01$, ***, $P < 0.001$, ****, $P < 0.0001$).

DNL343 treatment initiated at advanced stage of disease rescued premature mortality and reversed biomarkers of neurodegeneration in the eIF2B HOM mice

Having shown that DNL343 can robustly prevent ISR activation and disease phenotypes in the eIF2B HOM mouse, we tested the effectiveness of DNL343 to reverse disease in older eIF2B HOM mice after disease onset (based on clinical signs and plasma NfL ([Supplemental Figure 6B](#))). DNL343 was administered in food at a concentration of 100 mg/kg chow for 4 weeks starting when the animals were 19–26 weeks of age, which corresponded to an advanced disease stage ([Figure 7A](#)). As expected, and previously established, this led to robust unbound plasma and brain exposure that is equivalent to an oral gavage dose of 10 mg/kg ([Figure 7B](#), [Supplemental Figure 2A](#)). Within only 4 weeks of treatment, DNL343 fully restored normal body weight gain ([Figure 7C](#)) and reduced the elevated expression of ISR transcripts in the eIF2B HOM brain ([Figure 7D](#)), suggesting that administration of DNL343 can not only prevent ISR activation ([Figure 4D](#)), but also reverse it in animals with advanced disease. With this short duration of DNL343 treatment, neither motor function nor plasma NfL were fully rescued ([Supplemental Figure 6A and B](#)). Given the robust effects on both ISR markers and weight gain, we evaluated the effects of longer treatment with DNL343 in this treatment paradigm starting when the animals were 24–32 weeks of age ([Figure 7A](#), [Supplemental Figure 7A](#)), when independently generated eIF2B mutant mice were approaching their survival limit ([Dooves, Bugiani et al. 2016](#)). In line with our hypothesis, 20 weeks of DNL343 treatment normalized the elevated plasma NfL level in eIF2B HOM mice ([Figure 7E](#)). This dosing paradigm also reversed the increased level of plasma GFAP in eIF2B HOM mice and normalized it to wild-type control level ([Figure 7F](#)). Correction in these plasma biomarkers was accompanied by a robust extension of survival in the eIF2B HOM mice. As expected, in this 20-week study only 25% (N=3/12) of vehicle-treated eIF2B HOM mice survived to the end of the study. In contrast, 84.6% (N=11/13) of DNL343-treated eIF2B HOM mice survived beyond the study cessation ([Figure 7G](#) and [Supplemental Figure 7B](#)), confirming that DNL343 can reverse disease phenotype. Together these data demonstrate that DNL343 is a potent, CNS penetrant, ISR inhibitor that can correct or reverse downstream effects of chronic ISR overactivation.

Discussion

Increasing evidence suggests that the ISR plays a causative role in a broad range of CNS disorders such as ALS and VWMD ([Costa-Mattioli and Walter 2020](#), [Storkebaum, Rosenblum et al. 2023](#)). DNL343 is an investigational small molecule eIF2B activator that is developed to address ISR-mediated neurodegeneration. Here, we showed that DNL343 robustly inhibited the ISR in the CNS whether activated acutely by mechanical crush injury to the optic nerve or chronically by an eIF2B LOF mutation. DNL343 also exerted a neuroprotective effect in both models by preventing either degeneration of the RGC or elevation in a plasma biomarker of neurodegeneration, NfL, and motor function deterioration. Initiating DNL343 treatment after disease onset in the eIF2B LOF model led to equally robust inhibition of the ISR and even reversed the elevated levels of plasma markers of neurodegeneration, NfL, and neuroinflammation, GFAP, and prolonged survival in the model. Our study also put forth candidate biomarkers that were identified in the mouse model and cross validated in clinical samples from patients with VWMD to potentially enable clinical assessment of CNS ISR activation and modulation, and their downstream consequences. Together these data demonstrate the therapeutic effects of DNL343 in nonclinical *in vivo* settings and present clinical biomarker candidates.

DNL343 is a novel small molecule eIF2B activator that was engineered for high CNS penetration. Consistent with this, data across multiple dosing studies in mice showed that DNL343 achieved comparable unbound exposures in the plasma and brain. DNL343 exposure also showed a




Figure 7

Reduction in ISR activation in the CNS is associated with reversal and normalization of plasma biomarker of neurodegeneration and extension of life when DNL343 treatment was initiated towards end of disease stage in the eIF2B HOM mouse.

(A) Schematic of DNL343 therapeutic dosing studies in the eIF2B HOM mouse. DNL343 treatment was initiated when animals already presented with disease phenotypes at 19-26 or 24-33 weeks of age for 4 or up to 20 weeks, respectively. Mice self-administered DNL343-formulated rodent chow to achieve levels equivalent to oral gavage dose of 10 mg/kg. (B) DNL343 exposure was assessed in terminal plasma and in the brain after 4 weeks of dosing. (C) Body weight was measured at baseline and up to 4 weeks of dosing. (D) Heatmap visualization of select ISR transcript markers in the brain following vehicle- and DNL343 treatment for 4 weeks. (E-F) Plasma biomarker of neurodegeneration, NFL, and neuroinflammation, GFAP, was measured every 4 weeks for up to 20 weeks of dosing. (G) Kaplan-Meier graph shows that the reduced lifespan of the eIF2B HOM mice was extended when DNL343 treatment was initiated at 24-33 weeks of age. Data are presented as mean $\pm$ SEM of N=7-10 mice (panels B-D) or 10-13 mice per group (panels E-G). Statistical significance for DNL343 effect was set at $P < 0.05$ as determined by a mixed-effect analysis followed by multiple comparison tests against vehicle-dosed animals of the same genotype at matching timepoints (C) or against baseline values for each group (E-F). Effect of DNL343 on eIF2B HOM survival was assessed with Log-rank test. (*, $P < 0.05$. **, $P < 0.01$, ***, $P < 0.001$, ****, $P < 0.0001$).

favorable dose-dependent profile with no notable differences between healthy animals and disease models. In a chronic setting, DNL343 steady-state concentration was rapidly achieved and maintained, and the compound was well tolerated at above neuroprotective exposure levels in the ONC and eIF2B LOF models. In line with its preclinical pharmacokinetic data, DNL343 showed low pharmacokinetic variability and high CSF distribution in healthy volunteers and participants with ALS, supporting its progression as an investigational therapeutic for CNS indications (Sun, Tsai et al. 2023).

Data from our *in vivo* models showed that DNL343 can inhibit the ISR in multiple mouse models. In an acute ONC model, we showed significant ISR upregulation in the retina 2 days following ONC as previously reported (Larhammar, Huntwork-Rodriguez et al. 2017 [DOI](#)). This activation persisted but was less pronounced after 14 days suggesting that the ISR is activated most strongly as an early response to acute injury. At both time points, DNL343 dose-dependently normalized the ISR pathway leading to protection against RGC loss with mice treated at doses ≥ 3 mg/kg showing numbers of surviving RGCs that were comparable to that of uncrushed controls. The neuroprotective potential of ISR inhibition in the model was previously demonstrated using ISRIB (Larhammar, Huntwork-Rodriguez et al. 2017 [DOI](#)). In contrast to our data however, treatment with ISRIB at a higher and more frequent dose of 10 mg/kg (b.i.d.) led only to a partial correction of *Chac1* (an ISR marker that is assessed in both the published data and our study) and RGC survival. This points to improved potency as a potential differentiator between DNL343 and the previous generation ISR inhibitor. Another consideration could be that the greater extent of ISR activation seen in the published data (Larhammar, Huntwork-Rodriguez et al. 2017 [DOI](#)) exceeded the cellular threshold beyond which ISRIB would have no effect. To date, such a phenomenon had only been demonstrated *in vitro* in the context of sodium arsenite induced stress (Rabouw, Langereis et al. 2019 [DOI](#)); whether it also underlies the discrepancy in these *in vivo* studies remains to be evaluated. Other possible explanations include greater unbound DNL343 exposure in the brain owing to greater CNS penetration and/or lower protein binding, and improved cellular potency (Osipov 2022 [DOI](#)).

The robust ISR inhibition and neuroprotection in the acute nerve injury model led us to study the effect of DNL343 in chronic ISR-dependent neurodegeneration in an eIF2B LOF model. Our independently generated eIF2B LOF mouse exhibits features that are consistent with previously reported models, namely prominent ISR activation in the CNS that was detectable in early adulthood and persisted throughout life, accompanied by stunted body weight growth that does not appear to be driven by hypophagia, and motor function impairment (Dooves, Bugiani et al. 2016 [DOI](#), Abbink, Wisse et al. 2019 [DOI](#), Wong, LeBon et al. 2019 [DOI](#)). In addition, we showed a progressive escalation in the level of a plasma neurodegeneration biomarker, NfL, that corresponded to the degree of motor function loss. DNL343 treatment, initiated before overt disease manifestation, dose-dependently normalized these phenotypes with doses ≥ 3 mg/kg reverting body weight gain, plasma NfL level, and motor function to wild-type-like levels. While preventative modulation of some of the endpoints shown in this study is consistent with published literature utilizing other eIF2B activators (Abbink, Wisse et al. 2019 [DOI](#), Wong, LeBon et al. 2019 [DOI](#)), our data provided further insight to DNL343 effects not previously explored. Our longitudinal data on plasma NfL levels throughout the dosing study allowed us to observe that DNL343, at doses of 3 & 10 mg/kg, not only led to reduction but reversal of plasma NfL elevation that hinted at the potential for this molecule to reverse the consequences of chronic ISR activation. Indeed, when dosed in a therapeutic paradigm starting at ages that corresponded to end of life (Dooves, Bugiani et al. 2016 [DOI](#)), DNL343 not only suppressed ISR activation in the eIF2B LOF brain but also robustly reversed the elevated levels of plasma NfL and GFAP. Reduction in these markers were apparent after 8 weeks, but not at the earlier timepoint of 4 weeks of treatment and this timeframe appears consistent between the prophylactic and the therapeutic dosing studies, suggesting that resolution of active neurodegeneration & neuroinflammation is predicated on correction of upstream consequences of CNS ISR activation. Further, 4 weeks of therapeutic dosing with DNL343 did not restore motor function. While this was not further tested, we postulate that prolonging the

treatment may not lead to further improvement as motor neurons likely were already degenerated at the time of treatment initiation. On the other hand, longer treatment with DNL343 in the clinically relevant therapeutic dosing paradigm extended the otherwise shortened life span of the eIF2B LOF mouse with most mice surviving past 50 weeks of age when the study was terminated. These key insights that DNL343 can robustly inhibit the ISR, reverse disease biomarkers and extend life span in an *in vivo* model when treatment was administered after the onset of disease have direct clinical relevance and are a major step forward in understanding the therapeutic potential of eIF2B activators.

We conducted both targeted and unbiased analyses using brain, CSF, and plasma samples from DNL343-treated eIF2B LOF mice to discover biofluid based biomarkers that could be harnessed to monitor CNS ISR activation and modulation, and their downstream consequences in the clinic. We were surprised to find a disconnect between proteins that were altered in the eIF2B LOF mouse CSF relative to those in the brain. While bulk brain transcriptomic and proteomic analyses show consistent changes in transcripts and proteins that belong to the ISR and amino acid metabolism pathways, as previously published (Wong, LeBon et al. 2019 [DOI](#)), our CSF proteomic findings identify proteins that represent downstream disease consequences such as demyelination and neuroinflammation. These findings were replicated in 2 cohorts of animals at 3-4 and 5-7 months of age which correspond to stages before and when disease presentation becomes evident in the eIF2B LOF model, respectively, speaking to the robustness of the findings but also highlighting the early onset of neurodegeneration in the model that precedes functional manifestation. Chronic treatment with DNL343 corrected these genotype-associated changes in the respective samples. Targeted analyses of proteins led us to discover additional markers of the ISR and neuroinflammation that could be measured in biofluids. Increased transcript or protein level of GDF-15, GFAP, and TIMP-1 in the eIF2B LOF brain and their dose responsive modulation by DNL343 were reflected by their changes in the CSF (GDF-15 and TIMP-1) and plasma (GFAP). Of these, we showed that GDF-15, a transcriptional target of ATF4, and GFAP, a marker of neuroinflammation and reactive astrocytes, were also elevated in the CSF and plasma of patients with VWMD, a rare neurodegenerative indication that is caused by biallelic recessive mutations in *EIF2B1-5* and in which the ISR is a central mechanism. While astrocytes are heavily implicated in the pathophysiology of VWMD (Dietrich, Lacagnina et al. 2005 [DOI](#), van der Knaap, Pronk et al. 2006 [DOI](#)), astrocyte dysfunction is also increasingly being recognized to contribute to the initiation and progression of diverse neurodegenerative disorders (Brandebura, Paumier et al. 2023 [DOI](#)), so GFAP is of particular interest as a CNS biomarker. NfL, a marker of axonal degeneration that is increased and correlated with disease progression in other neurodegenerative conditions (Huang, Zhu et al. 2020 [DOI](#), Uphaus, Steffen et al. 2021 [DOI](#), Chelban, Nikram et al. 2022 [DOI](#)) and in the eIF2B LOF mouse model, was also significantly elevated in both the plasma and CSF from VWMD patients. Inflammatory markers, such as TIMP-1 and MCP-1, that we identified in the mouse model based on changes relative to wild-type control and dose responsiveness to DNL343 were unchanged in samples from patients with VWMD, highlighting contrasts that may be driven by species-specific differences. Nonetheless, the eIF2B LOF mouse serves as an important tool that models the biological consequences of chronic ISR activation in the CNS and from which biomarkers identified have broad applicability in other neurodegenerative indications. To this point, our DNL343 studies in two *in vivo* models allowed us to observe commonality in ISR transcript markers despite the distinct modes of activation and CNS tissues (acute activation in the retina after ONC and chronic activation in the eIF2B HOM brain). To our knowledge, our study is the first to perform multi-omics characterization of the CNS-adjacent and clinically accessible CSF in an ISR-dependent model of neurodegeneration. The biofluid-based candidate biomarkers we cross-identified in patients with VWMD – GDF-15, GFAP, and NfL – could serve as potential biomarkers to monitor the extent and consequences of ISR activation and therapeutic modulation in the clinic.

Acknowledgements

We thank the VWMD patients and their families for generously donating samples, and we extend our thanks to Dr. Raphael Schiffman and the Baylor Scott & White Research Institute for granting us permission to utilize these valuable patient samples in our research. Finally, the authors dedicate this work to the memory of our beloved colleague and friend, Patrick C. G. Haddick.

Disclosure

Competing Interests: E.Y, J.H.S, M.H.F, R.C, H.S, R.T, A.I.B, I.B, N.B.B, CL.C, T.E, A.A.E, A.G, C.H, K.R.H, R.M, H.N.N, M.O, Y.R, K.R, E.R, T.S, V.T, J.W.L, L.A.K, are current employees and shareholders of Denali Therapeutics. W.E.D, M.L, B.M, P.C.G.H, A.W.L, A.A.N., J.W, K.S.-L, P.E.S are former employees and shareholders of Denali Therapeutics.

Materials and methods

CSF and Plasma from VWMD patients and healthy controls


CSF and plasma from VWMD patients were obtained under a material transfer agreement with Baylor Scott & White Research Institute (Dallas, TX). Samples were collected 15-25 years prior to analysis. Plasma EDTA from healthy controls obtained from BioIVT, Allcells, and Denali Phase 1 clinical trial: NCT04268784. CSF from healthy controls obtained from Biochemed and Denali repository. Healthy control samples were collected 0-2 years prior to analysis.

Quanterix Simoa Assays in human samples

For CSF NfL measurements, CSF was diluted 100x and analyzed using Quanterix Simoa Neurofilament-Light (NfL) kit (Quanterix, # 103400) according to manufacturer's instructions on the Quanterix SR-X instrument. For plasma measurements of NfL and GFAP, plasma was diluted 4x and analyzed using Quanterix Simoa Neurology 4-Plex A (Quanterix, # 102153) kit according to manufacturer's instructions on the Quanterix HD-X instrument. Measurements were interpolated against a calibration curve provided with the Quanterix assay kit produced using on-instrument software. All assays run with technical replicates and results averaged.

Electrochemiluminescence-based detection (ECLIA) for the quantitation of (sTREM2) in human samples


MSD GOLD 96-well small spot streptavidin SECTOR plates (MSD, catalog # L45SA) were washed 3 times with 300 µL/well with wash buffer (1X TBST) using a plate washer. To each well, 1 µg/mL Human TREM2 biotinylated antibody, polyclonal goat IgG (R+D, catalog # BAF1828) diluted in PBS was added and the plate was incubated at RT for 1 hour on an orbital shaker at 700 rpm. Plates were washed 3 times with 300 µl wash buffer and blocked with 150 µl per well of MSD Blocker A (MSD, Catalog # R93AA) for 2 hrs at RT on an orbital shaker at 700 rpm. Plates were washed 3 times with wash buffer and sample or standard were added diluted in 25% MSD Blocker A in TBST. hTREM2-His tagged ECD protein standards were prepared at 4X dilutions starting at 50,000 pg/mL. Plates were incubated overnight (16-24 hours) at 4°C on an orbital shaker at 700 rpm. Plates were washed as above and sulfo-tagged Human TREM2 Antibody, polyclonal goat IgG (R+D, catalog # AF1828) detection antibody diluted 1:5000 in 25% MSD Blocker A in TBST was added to each well. Plates were incubated for 1 hr at Rt on an orbital shaker at 700 rpm. Plates were washed again and 150 µL per well of MSD Read Buffer T (MSD, catalog # R92TC-3) diluted 1:1 in water was added to each well. Plates were read on a 1201 MSD SECTOR 600MM plate reader (Meso Scale Discovery,



Supplemental Figure 1

The ISR is activated in the brain of the eIF2B HOM mice.


(A) Heatmap visualization of ISR mRNA markers in the brains of mice that are wildtype (WILD), heterozygous (HET) or homozygous (HOM) for the *Elf2b5 R191H* knock-in mutation. (B) Volcano plot showing the comparisons of eIF2B HOM to wild-type bulk brain samples (N=9-12/group, respectively) by RNA sequencing. Blue and red circles denote significantly up- or down-regulated genes (FDR < 5%), larger labelled points correspond to known ATF4 target genes. (C-D) Heatmap visualization of select ISR transcript markers in the PBMC and spleen. Animals were 13-19 weeks of age.



Supplemental Figure 2

DNL343 formulated food is well tolerated in both wild-type and homozygous mutant mice & targeted DNL343 are achieved.


(A) Brain DNL343 exposures following consumption of food formulated with DNL343 at 3, 10, 30 and 100 mg/kg chow was equivalent to those following single oral gavage at 0.3, 1, 3, and 10 mg/kg body weight. (B) Food intake estimated based on the difference in hopper weight and adjusted for body weight. Statistical significance was set at $P < 0.05$ as determined by a mixed-effect analysis followed by multiple comparison tests against vehicle-dosed animals of the same genotype at matching timepoints (*, $P < 0.05$. **, $P < 0.01$). (C) DNL343 intake was calculated based on estimated food intake and DNL343 concentration in the food. Data are presented as mean $\pm$ SEM of $N=8-18$ mice per group.



Supplemental Figure 3

Confirmation of ISR associated proteomics changes in bulk brain and CSF in a cohort of 5-7-month-old mice, establishing evidence for metabolomic perturbations in the eIF2B HOM mice relative to the wild-type controls.


(A) Volcano visualization of altered proteins in eIF2B HOM as compared to wild-type mice (N=3 per genotype). A total of 4,197 proteins were quantified. Variables with absolute log₂ FC ≥ 0.25 and P < 0.05 are labeled. Proteins with larger symbols have log₂ FC ≥ 0.5. Significant increases in SLC-mediated transmembrane transport proteins, serine metabolism, and decreases in lipid metabolism proteins that were shown in [Figure 3](#) were also seen in this independent cohort. (B) Corresponding proteomic changes in CSF proteome are shown. Proteins with absolute log₂ expression change > 0.25 and P < 0.05 are denoted in boxed labels. A total of 202 proteins were quantified and results show significant increases in abundance of protein biomarkers of brain microglial activation. (C) Metabolomic analysis of bulk brain associated with proteomic shifts shown in Panels A and B. Metabolites or lipids with absolute log₂ FC > 0.5 and P < 0.05 are labeled. As predicted by significant decreases in lipid metabolism proteins noted in the bulk brain of eIF2B HOM mice, levels of cholesterol esters and 7-keto-Cholesterol (oxidized cholesterol) were highly elevated in the bulk brain. Despite increases in SLC-mediated transmembrane amino acid transporter expression, brain alanine, TCA cycle intermediates, and methyl-donor and thiamine metabolic co-factors were all lower in eIF2B HOM mice. Statistical significance was set at P < 0.05 as determined by robust linear model. N=3/genotype.



Supplemental Figure 4

Elevation in GDF-15 mRNA and protein levels in the eIF2B HOM brain and correction by DNL343 is reflected by changes in the CSF.


(A-B) GDF-15 is increased on both the mRNA and protein level in the brain of eIF2B HOM mice relative to wild-type controls and 4 weeks of DNL343 in diet treatment at a dose equivalent to 10 mg/kg reduced its level. (C) Measurement of GDF-15 in the mouse CSF is feasible and shows changes that recapitulate findings in the brain. Data from the animal model is presented as mean $\pm$ SEM of N=7-11 mice per group. Statistical significance for DNL343 effect in the mouse model was determined by a two-way ANOVA followed by multiple comparison tests against vehicle-dosed animals of the same genotype (****, $P < 0.0001$).



Supplemental Figure 5

Evaluation of biomarkers for VWMD in patient CSF and plasma


(A) CSF and plasma protein levels of GDF-15 in patients with VWMD and healthy controls with age at time of collection shown. Data points from the same patient collected at different ages are connected with a solid black line. (B-C) Protein levels of IL-18 and sTREM2 measured in CSF and plasma of VWMD patients and healthy controls. (D) NfL protein levels measured in CSF and plasma of VWMD patients and healthy controls and age at time of collection. Data points from the same patient collected at different ages are connected by a solid black line. (E) Level of denoted proteins in plasma shown as relative level compared to average of healthy controls on log₂ scale in a heatmap. For patients with multiple samples, age increases from left to right across lanes. VWMD patient ID#s correspond across panel E (plasma) and [Figure 6S](#) (CSF). Plasma and CSF samples in the healthy control group are from non-matching/different individuals. Statistical significance for the difference between samples from VWMD patients and healthy controls was assessed on log₂ fold change data using Welch's t test (ns, not statistically significant).



Supplemental Figure 6

Four weeks of DNL343 treatment initiated at late stage of disease did not rescue motor function but led to a trend of plasma NfL reduction.

(A) Balance beam test was performed after 4 weeks of dosing and time to cross the beam out of 30 seconds were recorded. (B) Plasma biomarker of neurodegeneration, NfL, was measured at baseline and after 4 weeks of DNL343 dosing. Data are presented as mean $\pm$ SEM of N=7-12 mice per group. Statistical significance for DNL343 effect was set at $P < 0.05$ as determined by one-way ANOVA followed by multiple comparison tests against vehicle-dosed animals of the same genotype (A) or mixed-effect analysis followed by multiple comparison tests against vehicle-dosed animals of the same genotype at matching timepoints.



Supplemental Figure 7

Baseline characteristic and age at the end of the 20-week DNL343 therapeutic dosing study in the eIF2B HOM model.

(A) Age at DNL343 treatment initiation was matched across all experimental groups. (B) Age of mice at the end of the 20-week study or when animals met at least one of the predetermined humane endpoints. X indicates mice that died or met a humane endpoint during the 20-week dosing study.

catalog # IC1AA-0) within 30 minutes of adding buffer and data was captured in Methodical Mind (Meso Scale Discovery, version Fall 2020 (1.0.38)). Pg/ml concentrations for each sample were determined by MSD analysis software Discovery Workbench (Meso Scale Discovery, version LSR_4_0_13) using a 4-parameter logistic model. All assays run with technical replicates and results averaged.

MSD assays for additional biomarkers in human samples

CSF and plasma samples were analyzed according to manufacturer's protocol using the following MSD kits: R-PLEX Human GDF-15 Antibody Set (MSD, catalog # F21YD-3), R-PLEX Human TIMP-1 Antibody Set (MSD, catalog # F21YO-3), V-PLEX Human MCP-1 kit (MSD, catalog # K151NND-2), and U-PLEX Human IL-18 kit (MSD, catalog # K151VJK-2). For CSF only, samples were analyzed according to manufacturer's protocol using R-PLEX Human GFAP Antibody Set (MSD, catalog # F211M-3). Plates were read on a 1201 MSD SECTOR 600MM plate reader (Meso Scale Discovery, catalog # IC1AA-0) within 30 minutes of adding buffer and data was captured in Methodical Mind (Meso Scale Discovery, version Fall 2020 (1.0.38)). Pg/ml concentrations for each sample were determined by MSD analysis software Discovery Workbench (Meso Scale Discovery, version LSR_4_0_13) using a 4-parameter logistic model. All assays run with technical replicates and results averaged.

Animal care

All procedures in animals were performed with adherence to ethical regulations and protocols approved by Denali Therapeutics Institutional Animal Care and Use Committee. Mice were housed under a 12-h light/dark cycle (lights on at 7 AM, lights off at 7 PM) with *ad libitum* access to water and a standard chow (Labdiet, #5LG4) unless otherwise indicated. Whenever possible, animals were group housed of up to 5 sex-matched animals/cage.

DNL343 preparation for oral gavage dosing

DNL343 was prepared as a suspension in a 0.5% methylcellulose solution. Briefly, DNL343 was placed in individual glass vials to which purified water (half of the final volume), was added. The mixture was gently mixed using a probe sonicator at 40% amplitude for 10 times, each lasting for 20 seconds on pulse sonication. The result was a suspension with dispersed particles that was uniform throughout the product. Equal volume of a 1% methylcellulose (2X final target concentration, in half of final target volume) solution in purified water was added to the above suspension and vortexed until uniform. Suspension was visually inspected to be uniformly distributed. Dosing solutions were prepared on the first dosing day then weekly thereafter and were maintained at 4°C, on a laboratory rotator, until use. DNL343 suspension was remixed on dosing instances and administered *via* oral gavage at a volume of 10 ml/kg body weight.

DNL343 preparation for in diet dosing

DNL343 was blended in bacon flavored grain based rodent diet (PicoLab Mouse Diet 20, catalog #5058, gross energy 4.63 kcal/g) and pelleted by Bio-Serv. For every target dose in mg of DNL343/kg body weight per day, DNL343 was formulated based on an estimated daily food consumption of 0.1 kg of chow per kg body weight per day (e.g. 30 mg/kg chow for 3 mg/kg body weight). Bacon flavored base diet was used as placebo control. Coloring was added to differentiate between dosages and to blind experimenters to the treatments.

DNL343 in diet dosing

Animals were group housed whenever possible. Control or medicated food was weighed every week and refreshed every 4 weeks at minimum. Food intake was estimated by taking the difference in hopper weight, normalized for total body weight in each cage and presented per

diem. DNL343 intake was estimated by adjusting the food intake for DNL343 concentration in the food. DNL343 exposure in the plasma, collected *via* submandibular bleed as an in-life procedure or *via* cardiac puncture at terminal timepoints, and brain was measured using LC/MS/MS.

Tissue collection

For all tissue collection, animals were humanely anesthetized with 2.5% tribromoethanol. Whole blood was collected *via* cardiac puncture into EDTA coated tubes and spun down at 12,700 rpm for 7 minutes at 4 °C before collecting the top plasma layer for analysis. CSF, if collected, was then extracted *via* cisterna magna puncture, spun down at 12,700 rpm for 7 minutes at 4 °C, following which the supernatant was collected and stored in a new tube for analysis. Animals were transcardially perfused with ice-cold PBS. Tissues were then collected, weighed, frozen on dry ice and stored at 80 °C for subsequent analysis.

Optic Nerve Crush

Optic nerve crush (ONC) was performed as previously described by (Watkins, Wang et al. 2013 [↗](#)) on 12-week-old wild-type male C57Bl/6J mice obtained from the Jackson Laboratory (USA). Animals were deeply anesthetized with inhaled isoflourane. The left eye of each animal was subjected to optic nerve injury *via* an intraorbital approach. An incision was made on the superior conjunctiva of the left eye, and the optic nerve was exposed. The crush injury was inflicted for 10 seconds using a 45° angled fine tip forceps 1-3 mm from the eyeball. Post-operatively, a drop of 0.5% proparacaine hydrochloride ophthalmic solution was applied to the affected eye as an analgesic measure. A small amount of ophthalmic ointment was applied to the non-procedural eye prior to surgery to prevent drying. Unoperated right eyes (contralateral to the crushed site) were used as controls. Starting from 3 hours after the ONC procedure, mice were administered vehicle or DNL343 at doses of 0.75, 3, or 12 mg/kg once daily *via* oral gavage. Animals were humanely euthanized on day 2 after ONC (2 hours after the last dose) or on day 14 (20 hours after the last dose).

Generation of the eIF2B LOF mouse

The *Eif2b5* R191H knock-in mouse model was engineered and maintained on a C57BL/6J background by Ozgene (Australia) using the goGermlineTM technology (Koentgen, Lin et al. 2016 [↗](#)). Briefly, a targeting vector was designed against the mouse *Eif2b5* gene containing a CGC to CAC codon substitution to replace arginine for histadine at amino acid position 191 in exon 4. An FRT-flanked neomycin selection cassette was targeted between exon 5 and 6 and Flp-mediated recombination was used to excise this cassette. The colony was maintained by heterozygous breeding to obtain littermate wild-type and homozygous knock-in animals. The mouse genotypes were confirmed by PCR.

DNL343 preventative dosing in the eIF2B LOF model

10-17-week-old eIF2B HOM and their wild-type littermates were assigned to receive food containing DNL343 at concentrations of 30-100 mg/kg or base chow. Groups were balanced for differences in body weight, age and sex within each genotype. Food weight and body weight were assessed weekly. Plasma was collected at baseline and every 2 weeks starting at 2 hours after the onset of the light period. Motor function was assessed by a balance beam test after 12 weeks of treatment. Animals were humanely euthanized between 12.9-13.3 weeks of treatment. Mice from all groups are represented on each consecutive necropsy day.

DNL343 therapeutic dosing in the eIF2B LOF model

19-26-week-old eIF2B HOM and their wild-type littermates were assigned to receive food containing DNL343 at a concentration of 100 mg/kg or base chow, accounting for differences in body weight, age, sex and plasma NfL level within each genotype. The body weight was assessed at

baseline and after 19 and 28 days of treatment. Motor function was assessed by a balance beam test after 27 days of treatment. Animals were humanely euthanized after 33 days of treatment.

Another cohort of eIF2B HOM and wild-type littermates were treated with DNL343-formulated diet (100 mg/kg chow) or base diet from 24–33 weeks of age for up to 20 weeks. Body weight was assessed at baseline and weekly after. Plasma was collected before and every 4 weeks after study initiation. Animals meeting any one of the following humane endpoints were euthanized: body weight loss of $\geq 10\%$, hindlimb paralysis, or inability to right itself within 20 seconds.

Balance Beam Test

To assess balance and motor coordination, animals were trained to walk along a 98.5 cm long x 13 mm diameter wooden beam, elevated at 40 cm above the bench surface lined with a soft foam mattress (104 x 74 x 10 cm). A length of 80 cm was marked on the beam as the distance the animals were required to cross. A spotlight was placed at the starting end to serve as an aversive stimulus. A dark enclosure (black matte acrylic box, 20 x 15 x 20 cm) with bedding material and carton tube was placed at the opposite end to serve as an escape box with a more agreeable condition. A video camera was set in front of the starting end to record foot slips as the animal progressed across the beam.

Animals underwent 3 training runs one day prior to the testing. Each mouse was first placed in the escape box for about 1 minute, then placed at an increasing distance away from the escape box over 3 trials. If an animal paused on the beam, or tried to turn and advance the wrong way, it was gently touched on the hindquarters and encouraged to keep moving toward the escape box. Animals were habituated to the experimental room for at least one hour prior to testing. To begin an experiment, each subject was placed on the starting end of the beam and allowed a cutoff time of 30 seconds (s) to cross. The elapsed time was only recorded while the subject actively moved towards the finish line. If a fall occurred, the subject was restarted at the beginning of the beam. Each subject was given three attempts to complete the balance beam. If a subject failed all three attempts, it was assigned a time of 30 s and a value of 3 falls. The number of foot slips was quantified from the video recording only if the animal completed the task. The balance beam was cleaned with a 70% solution of isopropanol and dried between each subject. The escape box was cleaned with isopropanol and dried, and the bedding and carton tube replaced between animals of different cages. The experiment was video recorded. Time to traverse the beam and number of falls were recorded live by an experimenter who was blinded to the genotypes of the animals. Foot slip scoring was done post-hoc by another experimenter, who was blinded to both genotypes and treatment, using the video recordings.

DNL343 pharmacokinetics

Plasma and brain concentrations of DNL343 were measured using LC-MS/MS by Quintara Discovery. Brain samples were homogenized in 3 volumes of ice-cold water, then further diluted 2-fold with blank mouse plasma. An aliquot of 20 μL of plasma sample or plasma diluted brain homogenate was extracted with 100 μL of acetonitrile containing internal standard (warfarin). The mixture was vortexed on a shaker for 15 minutes and subsequently centrifuged at 4000 rpm for 15 minutes. An aliquot of 70 μL of the supernatant was mixed with 70 μL of 35% acetonitrile in water with 0.1% formic acid for injection to the LC-MS/MS. Calibration standards and quality control samples were prepared by dilutions of the 2 mg/mL DNL343 stock solution with 70% acetonitrile added to blank mouse plasma. These standards and QC samples were extracted alongside unknown samples in each bioanalytical batch. The final extracts were analyzed by reversed-phase liquid chromatography and negative electrospray ionizations (LC-MS/MS) with multiple reaction-monitoring (MRM) of the test article and the internal standard. The standard curve was fitted by linear regression to quantify DNL343 in the matrix using Analyst 1.6.3

software (AB Sciex). Total DNL343 concentrations were adjusted for brain or plasma protein binding (fraction unbound, f_u) that were determined *in vitro* via an ultracentrifugation method and expressed as unbound (free DNL343) exposures.

qPCR Gene Expression Analysis

For analysis of gene expression after ONC, retinas from the left and right eyes were collected into RNeasy Protect (Qiagen, catalog # 76104) and stored at room temperature until further processing. RNA from the retina was isolated using the RNeasy Plus Micro kit (Qiagen, catalog # 74034). RNA from the brain using the RNeasy Plus Mini Kit (Qiagen, catalog # 74134). RNA was reverse transcribed into cDNA using the Fluidigm Reverse Transcriptase Master Mix (Fluidigm, catalog # 100-6298). Specific target amplification of cDNA was done per manufacturer's recommendations as the initial step for the real time qPCR on the Biomark HD system (Fluidigm, catalog # BMKHD-BMKHD). Briefly, 20X TaqMan assays were pooled and diluted with DNA Suspension Buffer (Teknova, catalog # T0221) to a final concentration of 0.1X of each assay. PCR reactions were carried out for each cDNA sample with the Taqman assay pooled in 5 μ L volumes, each containing 1.2 μ L of the pooled assay mix, 1 μ L PreAmp Master Mix (Fluidigm, # 100-5580), 1.5 μ L of H₂O, and 1.25 μ L of cDNA. The preamplification PCR was performed at one cycle of 95 °C for 2 minutes, followed by 14 cycles of 95 °C for 15 seconds and 60 °C for 4 minutes, and then 4 °C. Specific target amplification products from the PCR reactions were diluted 5x with DNA Suspension Buffer (Teknova, catalog # T0221). Gene expression analysis was carried out using the 96.96 dynamic arrays IFC (Fluidigm, catalog # BMK-M-96.96) on the Biomark HD system (Fluidigm, catalog # BMKHD-BMKHD). 10x assay mixture and sample pre-mix were prepared, with each assay being prepared in triplicates. Each 10x assay mix contained 2.5 μ L of 20x TaqMan gene expression assay (ThermoFisher) and 2.5 μ L of 2X Assay Loading Reagent (Fluidigm, catalog # 100-7611). All qPCR TaqMan probes (FAM) were ordered from Thermo Fisher Scientific (see Key Resources Table). Sample pre-mix was made by combining 2.5 μ L TaqMan Fast Advance PCR Master Mix (Applied Biosystems, catalog # 4444557), 0.25 μ L of 20X GE Sample Loading Reagent (Fluidigm, # PN 100-7610) and 2.5 μ L pre-amplified cDNA. IFC controller (Fluidigm, catalog # 68000112 I1) were used to prime the 96.96 dynamic arrays IFC Chip (Fluidigm, catalog # BMK-M-96.96) with the 96.96 control line fluid (Fluidigm, catalog # 89000021). 5 μ L of each assay and sample mix was then transferred into the appropriate inlets of the primed chip and loaded with the IFC controller. The PCR was performed at 70 °C for 40 minutes, 60 °C for 30 seconds, 98 °C for 1 minute, followed by 35 cycles of 97 °C for 5 seconds, 60 °C for 20 seconds. The data was analyzed with Fluidigm Genetic Analysis software. For relative quantification, the amount of target gene expression was normalized to the geometric means of Actb, Gapdh, and Ubb expression, relative to samples from vehicle-dosed controls and was calculated using the 2-Ct method. The data were analyzed with Real-Time PCR Analysis Software (Fluidigm).

Assessment of RGC survival

For immunofluorescence analysis of RGC survival and axonal degeneration, the left (ipsilateral to crush) and right eyes were collected 14 days after the ONC procedure and immediately fixed in 4% paraformaldehyde on ice for 1 hour. Retinas were then dissected from the eyes for wholemount staining. The degree of RGC loss and axonal degeneration at 14 days after ONC was assessed from whole-mount retinas. Floating whole mouse retinas were blocked in 5% normal goat serum in 0.5% Triton X-100 in PBS at 4°C for 2 hours. Primary antibodies were incubated over two nights at 4°C, followed by rinsing and incubation with secondary antibodies in PBS. Immunohistochemistry was performed using the following antibodies: rabbit anti γ -synuclein (1:200, Abcam, ab55424) and mouse anti TuJ1 (1:40, BioLegend, 801203). Retinas were mounted on slides after being cut with four incisions along the radial axes. Retinas were imaged using a spinning disk confocal microscope (Cell Observer CSU-X1, Carl Zeiss MicroSystem). Images were processed for brightness and contrast in Adobe. RGCs, identified as TuJ1 and γ -synuclein double-immunopositive cells, were

quantified manually. Retinal axon degeneration was scored based on density of axon bundles immunolabelled with TUJ-1, using a graded scale from 0–5, where 0 corresponds to no degeneration, and five to complete degeneration.

Detection of plasma NfL

Plasma NfL concentrations were measured using Simoa NF-Light® Advantage (SR-X version, Quanterix Catalog # 103400) or the Simoa® Neurology 4-plex A Advantage (HD-X version, Quanterix Catalog # 102153) bead-based digital ELISA kit and read on the Quanterix SR-X or HD-X instrument. All experiments were performed according to kit and instrument instructions as provided by Quanterix. All additional equipment and consumables were procured through Quanterix. Plasma samples were diluted 20x with Sample Diluent (Quanterix Catalog # 103399) before being added to Simoa 96-well microplates (Quanterix Catalog # 101457) alongside kit calibrators and controls. Kit-specific instructions were followed and sample NfL levels were measured using the NF Light analysis protocol on the Quanterix SR-X or Neurology 4-Plex A analysis protocol on the Quanterix HD-X instrument and interpolated against a calibration curve provided with the Quanterix assay kit. Mouse NfL data generated from the two instruments have been established to be comparable (data not shown).

Detection of plasma GFAP

Plasma GFAP was measured using the Simoa Neurology 4-plex A bead-based digital ELISA kit and read on the Quanterix HD-X instrument as described above.

Preparation of brain homogenate for protein analyses

Brains were homogenized in Radio-Immunoprecipitation Assay Buffer (Teknova) made with cComplete Protease Inhibitor (Roche, Catalog #04693132001) and PhosStop (Roche, Catalog # 04906837001) using the Qiagen TissueLyzer II (Cat No./ID: 85300) for 2 rounds of 3 minutes at 30 Hz. Homogenate was incubated on ice for 20 minutes and spun at 21,100 g for 30 minutes at 4 °C. Subsequent lysate was transferred to a clean 96-well deep plate. Protein concentration of the supernatant was measured with the bicinchoninic acid assay (Pierce™ BCA Protein Assay Kit).

Detection of GDF-15, TIMP-1, and MCP-1

ELISA kits were used to determine the levels of GDF15 (mouse/rat GDF15 Quantikine ELISA Kit, R&D Systems, catalog # MGD150), TIMP-1 (mouse TIMP-1 Quantikine ELISA Kit, R&D Systems, catalog # MTM100) and MCP-1 (Mouse CCL2/JE/MCP-1 Quantikine ELISA Kit, R&D Systems, catalog # MJE00B) in the brain, plasma, or CSF samples.

RNA-Seq library preparation

RNA from bulk mouse brain tissue was extracted using the RNeasy Plus Mini Kit (Qiagen) and resuspended in nuclease-free water. Libraries were generated using the QuantSeq 3' mRNA-seq Library Prep Kit FWD for Illumina (Lexogen A01173) with the UMI second strand synthesis module to identify and remove PCR duplicates, following the protocol defined by the manufacturer. Briefly, total RNA was used as input for oligo dT priming during reverse transcription, followed by RNA removal. Unique Molecular Identifiers were introduced during second strand synthesis and cDNA was purified using magnetic beads followed by 14 cycles of PCR with dual indexes and PCR purification. Library quantity and quality were assessed with Qubit 1X dsDNA HS Assay Kits (Invitrogen Q33231) and Bioanalyzer High Sense DNA chip (Agilent 5067-4626). Libraries were pooled in equimolar ratios and sequencing reads were generated on an Illumina NovaSeq 6000 instrument (100 bp single end) by SeqMatic (Fremont, CA, USA).

RNA-Seq data preprocessing

Sequencing adapters were trimmed from the raw reads with skewer (version 0.2.2) (Jiang, Lei et al. 2014 [\[1\]](#)). Reads were aligned to the mouse genome version GRCm38_p6. A STAR index (version 2.7.1a) (Dobin, Davis et al. 2013 [\[2\]](#)) and built with the `--sjdbOverhang=50` argument. Splice junctions from Gencode gene models (release M17) were provided via the `--sjdbGTFfile` argument. STAR alignments were generated with the following parameters: `--outFilterType BySJout`, `--quantMode TranscriptomeSAM`, `--outFilterIntronMotifs RemoveNoncanonicalUnannotated`, `--outSAMstrandField intronMotif`, `--outSAMattributes NH HI AS nM MD XS` and `--outSAMunmapped Within`. Alignments were obtained with the following parameters: `--readFilesCommand zcat` `--outFilterType BySJout` `--outFilterMultimapNmax 20` `--alignSJoverhangMin 8` `--alignSJDBoverhangMin 1` `--outFilterMismatchNmax 999` `--outFilterMismatchNoverLmax 0.6` `--alignIntronMin 20` `--alignIntronMax 1000000` `--alignMatesGapMax 1000000` `--quantMode GeneCounts` `--outSAMunmapped Within` `--outSAMattributes NH HI AS nM MD XS` `--outSAMstrandField intronMotif` `--outSAMtype BAM SortedByCoordinate` `--outBAMcompression 6`. Gene level counts were obtained using featureCounts from the subread package (version 1.6.2) (Liao, Smyth et al. 2014 [\[3\]](#)). Gene symbols and biotype information were extracted from the Gencode GTF file.

RNA-Seq differential Expression analysis

Following alignment and expression quantitation, differential expression analysis was performed using the limma/voom framework (Law, Chen et al. 2014 [\[4\]](#)). Only samples with at least one million total counts were included in the analysis. To account for remaining differences in library sequence depths, size factors were calculated with the TMM method (Robinson and Oshlack 2010 [\[5\]](#)). Genes below the lower limit of quantitation were excluded using the `filterByExpr` function from the edgeR R package (version 3.42.4) (Robinson, McCarthy et al. 2010 [\[6\]](#)). A linear model with the following independent variables was fit for each protein-coding gene with the `voomWithQualityWeights` function: genotype, sex and age. The comparison of interest was extracted with the `eBayes` function from the limma R package (version 3.56.2), applying using the robust empirical Bayes procedure of (Phipson, Lee et al. 2016 [\[7\]](#)). Genes with FDR <5% were considered significantly differentially expressed.

Gene set enrichment analysis

To compare the expression changes caused by eIF2B loss of function in our study with previous observations, we retrieved the differential expression results published by Wong et al. ([\[8\]](#) Wong, LeBon et al. 2019 [\[8\]](#)) and performed gene set enrichment analysis (GSEA) with the `geneSetTest` algorithm from the limma R package. The most significantly upregulated genes reported by Wong et al. (e.g. top 100, 200, 300, 400 or 500 genes ordered by Bayes factor) were highly enriched among genes with large t-statistics in our dataset ($p\text{-value} < 10^{-20}$). Similar results were obtained with other GSEA algorithms, including camera and fgsea.

Proteomic analysis of the eIF2B LOF brains and CSF

Proteomics analysis was conducted at BGI Americas (San Jose, CA). For mouse CSF, samples were processed via an in-solution digest. Briefly, 4 μ l CSF per sample was reduced with DTT and alkylated with iodoacetamide (IAM). 100mM HEPES pH 8.5 was added and the samples were digested overnight with Tryp/LysC. The digestion was quenched with 10% TFA, desalted using C18 PhyTips (PhyNexus) and dried by SpeedVac and reconstituted in 100mM HEPES, pH 8.5. Samples were assigned respective TMT channels in one of four 8-plexes with the final channel being a pool of all the samples to normalize between TMT plexes. Samples were labelled with respective 8-plex TMT channels at room temperature for 1 hour. Approximately 1% of sample from each channel were mixed, dried down, stage-tipped and injected into the mass spec for label check then the

reaction was quenched with 5% hydroxylamine, mixed in equal amounts, dried down and cleaned up using C18 PhyTips (PhyNexus). For mouse CSF, due to the low sample amount no fractionation was performed prior to injection on the MS.

Tissue samples were lysed in 5% SDS in triethylammonium bicarbonate, pH 7.1 and assayed for concentrations. 6 µg of each sample was processed using the STRap MS sample prep device according to the manufacturer's protocol (Protifi). More specifically: samples were reduced with dithiothreitol (DTT) and alkylated with iodoacetamide (IAM); the IAM reaction was then quenched with DTT; the resulting samples were digested in the STRap device with Trypsin/Lys-C overnight. Digested samples were eluted from the STRap according to the manufacturer's protocol. An aliquot of 1 µg was taken from each eluted sample; and the aliquots were pooled to form a composite for TMT bridging. 4 aliquots of 5 µg were taken out as 4 TMT bridges, with each bridge being used for each TMT batch. All samples were dried by SpeedVac. The samples were reconstituted with 50mM TEAB pH 8.5 and incubated with their assigned TMT channels for 1 hour at room temperature. For each of the four TMT batches: the same amount of each TMT-labelled sample was aliquoted; and the aliquots were pooled and mixed with 1% formic acid. The 4 resulting mixtures were loaded onto the nano LC-MS/MS system for Label Check. After the Label Check was passed, all samples were dried by SpeedVac and reconstituted with 2% formic acid. The reconstituted samples of each batch were combined. The resulting three mixtures were further desalted using EVOLUTE® EXPRESS ABN according to the manufacturer's protocol (Biotage). The eluted samples were dried by SpeedVac, reconstituted with high-pH reversed-phase buffer A, and loaded onto the offline HPLC for fractionation. Either 8 or 12 fractions were obtained from each sample batch.

All samples were reconstituted with mobile phase A and loaded onto the nano LC-MS/MS system. The same amount of each reconstituted sample was injected for analysis with TMT method on a QE HF-X or Orbitrap Eclipse MS. Peptide search was performed with Sequest HT and TMT quantification was performed with the reporter ions node in Proteome Discoverer 2.5 (PD, Thermo Fisher). Data was searched against reviewed mouse sequences in Uniprot, full trypsin digest, and 20 ppm precursor and 0.5 Da fragment tolerance. N-terminal and Lysine TMT6plex and C carbamidomethyl were set as static modifications, oxidized M and N-terminal acetylation were set as dynamic modifications.

Metabolomic analysis of the eIF2B LOF brains

Sample preparation: 20 mg of snap frozen brain tissues were bead homogenized using 5 mm stainless steel bead (QIAGEN Cat#69989) in 0.4 ml of methanol:water (80:20 v/v; LC-MS grade) solution containing 64 stable internal standards. These samples were homogenized with Tissuelyser for 30 sec at 25 Hz in 4 °C. Crude homogenates were centrifuged at 21,000 x g for 20 min at 4 °C. Resulting supernatants were collected and transferred to 96 glass well plates (Analytical Sales, PN 27350). Two µl of CSF samples were diluted with 8 µl of 18 mW water and centrifuged at 21,000 g for 10 min at 4 °C. To these samples, 100 µl of MS-grade methanol containing 64 stable isotope internal standards was added and vortexed for 5 min at 4 °C. Samples were incubated at -20 °C for 1 hr and subsequently centrifuged at 21,000 x g for 20 min at 4 °C. Resulting supernatants were collected and transferred to 96 glass well plates (Analytical Sales, PN 27350).

Polar metabolomics analysis

Metabolomics analyses were performed using the UHPLC UHPLC ExionLC system coupled to Sciex QTRAP 6500+ electrospray mass spectrometer in positive and negative ionization modes. For positive ionization mode, 5 µL of sample was injected on a BEH amide 1.7 µm, 2.1×150 mm column (Waters Corporation, Milford, Massachusetts, USA) using a flow rate of 0.40 mL/min at 40°C. Mobile phase A consisted of water with 10 mM ammonium formate + 0.1% formic acid. Mobile phase B consisted of acetonitrile with 0.1% formic acid. The gradient was programmed as follows: 0.0–1.0 min at 95% B; 1.0–7.0 min to 50% B; 7.0–7.1 min to 95% B; and 7.1–10.0 min at 95% B. For

negative ionization mode, Samples N2 dried and reconstituted in 0.1% formic acid. For each analysis, 5 μ L of sample was injected on an Imtakt Intrada Organic Acid 3 μ m, 2 x 150 mm (Imtakt USA, Portland, OR USA); using a flow rate of 0.2 mL/min at 60°C. For negative ionization mode, Mobile phase A consisted of acetonitrile/water/formic acid = 10/90/0.1%. Mobile phase B consisted of acetonitrile/ 100mM ammonium formate= 10/90%. The gradient was programmed as follows: 0.0–1.0 min at 0% B; 1.0–7.0 min to 100% B; 7.1 at 0% B; and 7.1–10 min at 0% B. Mass spectrometry setting for the positive mode was as follows; curtain gas at 30 psi; collision gas was set at medium, ion spray voltage at 5500 V; temperature at 600°C; ion source Gas 1 at 50 psi; ion source Gas 2 at 60 psi; entrance potential at 10 V; and collision cell exit potential at 12.5 V. For the negative mode, settings were similar to positive mode with the following modifications: ion spray voltage at -4500 V, entrance potential at -10 V and collision cell exit potential at -15 V. Peaks were identified and integrated using Multiquant 3.02 (Sciex) based on known retention time and mass transitions and normalized to prespecified stable isotope internal standards. Area ratios were exported as all columns report and used for subsequent data analysis.

Lipidomics analysis

Methanol extracted samples from above were analyzed in electrospray positive and negative ionization modes. For positive ionization mode, Mobile phase A consisted of 60:40 acetonitrile/water (v/v) with 10 mM ammonium formate + 0.1% formic acid; mobile phase B consisted of 90:10 isopropyl alcohol/acetonitrile (v/v) with 10 mM ammonium formate + 0.1% formic acid. For negative ionization mode, Mobile phase composition was same as in positive mode with the exception that 10 mM ammonium acetate and 0.1% acetic acid were used as fortificants. Mass spectrometer settings for positive ionization mode were as follows: curtain gas at 40 psi; collision gas was set at medium; ion spray voltage at 5500 V; temperature at 250°C; ion source Gas 1 at 55 psi; ion source Gas 2 at 60 psi; entrance potential at 10 V; and collision cell exit potential at 12.5 V. Source settings for negative ionization mode were as follows: curtain gas at 30 psi; collision gas was set at medium; ion spray voltage at -4500 V; temperature at 600°C; ion source Gas 1 at 55 psi; ion source Gas 2 at 60 psi; entrance potential at -10 V and collision cell exit potential at -15.0 V. Lipidomics analysis in positive and negative ionization modes were initiated with 5 μ L of sample injection using a BEH C18 1.7 μ m, 2.1x100 mm column (Waters) as stationary phase with 0.25 mL/min flowrate and column temperature set at 55°C. The gradient was programmed as follows: 0.0–8.0 min from 45% B to 99% B, 8.0–9.0 min at 99% B, 9.0–9.1 min to 45% B, and 9.1–10.0 min at 45% B.

Data pre-processing and analysis for proteomics and metabolomics. Proteomics data pre-processing

TMT data preprocessing was performed using the MSstatsTMT package (2.4.1). Data were median centered and log2 transformed. Features with all missing measurement, shared peptides, or proteins with single feature, features with less than 3 measurements within each run were removed from analysis. All protein features with ≤ 1 feature missing were included in the analysis. Nine proteins with one missing value were imputed using kNN function in VIM package (6.2.2).

Metabolomics and lipidomics data preprocessing

Metabolite/lipid features detected in at least 70% of samples were retained for further analysis. Partially missing values in 44 metabolite/lipid features were imputed using the kNN function in the VIM package. Unwanted variations in data not stemming from relevant biological factors (experimental groups) of interest were detected and removed using the RUV4 function in the ruv (0.9.7.1) package. Top 20th percentile of most abundant Metabolite/lipid features with lowest 10th percentile CV from wild-type control mice were selected as negative control features. RUV adjusted data were used for downstream analysis described below.

Differential expression analysis for proteomics and metabolomics

Unsupervised principal component analysis was performed the FactoMineR (2.8) package. Log₂ transformed data were scaled prior to analysis. Univariate analysis of differentially expressed proteins or metabolites were analyzed using limma (3.54.2). Sample specific quality weights were calculated with arrayWeights default method setting. For linear model analysis, a no-intercept model containing the experimental groups of interest (genotype or combination of genotype, treatment, and dose) and covariates (batch) was created. Following linear modeling with lmFit function, contrasts between groups were created using the contrast.fit function to assess group-wise differences. A robust Empirical Bayes moderation was performed with robust argument set to TRUE and minimum logFC set to 1.1. False discovery rate was assessed using the Benjamini-Hochberg procedure. Box plots, volcano plots and heatmaps were generated using the ggplot2 (3.4.2). EnhancedVolcano (1.14), and pheatmap (1.0.12) R packages. Feature overlap and venn diagram analysis were performed using the VennDiagram (1.7.3) package. Mouse reactome pathway enrichment analysis was conducted using the Fast Geneset Enrichment Analysis fgsea (1.24.0) R package. Protein ranks were created using moderated t-statistics and significance was estimated by permuting the proteins in the analysis set to create random assignments. A total of 10,000 permutations were used for estimation of enrichment p-values and normalized enrichment scores (NES). All analyses were conducted using R (4.2.1)

Statistical analysis

Data are reported as means $\pm$ SEM or as indicated in figures. Statistical analysis of data was performed in GraphPad Prism version 8 or later. Analysis of data from animal studies was performed using t test or one-way analysis of variance (ANOVA) with multiple comparison, or two-way ANOVA followed by multiple comparison test for data obtained from repeated measures of the same subjects. Analysis of data from human samples was assessed on log₂ fold change data using Welch's t test.

References

- Abbink T. E. M. *et al.* (2019) **Vanishing white matter: deregulated integrated stress response as therapy target** *Ann Clin Transl Neurol* **6**:1407–1422
- Abdelhak A. *et al.* (2022) **Blood GFAP as an emerging biomarker in brain and spinal cord disorders** *Nat Rev Neurol* **18**:158–172
- Abdulkarim B. *et al.* (2015) **A Missense Mutation in PPP1R15B Causes a Syndrome Including Diabetes, Short Stature, and Microcephaly** *Diabetes* **64**:3951–3962
- Adomavicius T., Guaita M., Zhou Y., Jennings M. D., Latif Z., Roseman A. M., Pavitt G. D. (2019) **The structural basis of translational control by eIF2 phosphorylation** *Nat Commun* **10**
- Bogorad A. M., Lin K. Y., Marintchev A. (2018) **eIF2B Mechanisms of Action and Regulation: A Thermodynamic View** *Biochemistry* **57**:1426–1435
- Borck G. *et al.* (2012) **eIF2gamma mutation that disrupts eIF2 complex integrity links intellectual disability to impaired translation initiation** *Mol Cell* **48**:641–646
- Brandebura A. N., Paumier A., Onur T. S., Allen N. J. (2023) **Astrocyte contribution to dysfunction, risk and progression in neurodegenerative disorders** *Nat Rev Neurosci* **24**:23–39
- Bugiani M., Vuong C., Breur M., van der Knaap M. S. (2018) **Vanishing white matter: a leukodystrophy due to astrocytic dysfunction** *Brain Pathol* **28**:408–421
- Chelban V. *et al.* (2022) **Neurofilament light levels predict clinical progression and death in multiple system atrophy** *Brain* **145**:4398–4408
- Chen H. H., Tarn W. Y. (2019) **uORF-mediated translational control: recently elucidated mechanisms and implications in cancer** *RNA Biol* **16**:1327–1338
- Chou A., Krukowski K., Jopson T., Zhu P. J., Costa-Mattioli M., Walter P., Rosi S. (2017) **Inhibition of the integrated stress response reverses cognitive deficits after traumatic brain injury** *Proc Natl Acad Sci U S A* **114**:E6420–E6426
- Costa-Mattioli M., Walter P. (2020) **The integrated stress response: From mechanism to disease** *Science*
- Dietrich J., Lacagnina M., Gass D., Richfield E., Mayer-Proschel M., Noble M., Torres C., Proschel C. (2005) **EIF2B5 mutations compromise GFAP+ astrocyte generation in vanishing white matter leukodystrophy** *Nat Med* **11**:277–283
- Dobin A., Davis C. A., Schlesinger F., Drenkow J., Zaleski C., Jha S., Batut P., Chaisson M., Gingeras T. R. (2013) **STAR: ultrafast universal RNA-seq aligner** *Bioinformatics* **29**:15–21
- Dooves S. *et al.* (2016) **Astrocytes are central in the pathomechanisms of vanishing white matter** *J Clin Invest* **126**:1512–1524

- Fogli A., Wong K., Eymard-Pierre E., Wenger J., Bouffard J. P., Goldin E., Black D. N., Boespflug-Tanguy O., Schiffmann R. (2002) **Cree leukoencephalopathy and CACH/VWM disease are allelic at the EIF2B5 locus** *Ann Neurol* **52**:506–510
- Gaetani L., Blennow K., Calabresi P., Di Filippo M., Parnetti L., Zetterberg H. (2019) **Neurofilament light chain as a biomarker in neurological disorders** *J Neurol Neurosurg Psychiatry* **90**:870–881
- Gebauer F., Hentze M. W. (2004) **Molecular mechanisms of translational control** *Nat Rev Mol Cell Biol* **5**:827–835
- Gordiyenko Y., Llacer J. L., Ramakrishnan V. (2019) **Structural basis for the inhibition of translation through eIF2alpha phosphorylation** *Nat Commun* **10**
- Halliday M. *et al.* (2015) **Partial restoration of protein synthesis rates by the small molecule ISRIB prevents neurodegeneration without pancreatic toxicity** *Cell Death Dis* **6**
- Hanson F. M., Hodgson R. E., de Oliveira M. I. R., Allen K. E., Campbell S. G. (2022) **Regulation and function of eIF2B in neurological and metabolic disorders** *Biosci Rep* **42**
- Harding H. P., Novoa I., Zhang Y., Zeng H., Wek R., Schapira M., Ron D. (2000) **Regulated translation initiation controls stress-induced gene expression in mammalian cells** *Mol Cell* **6**:1099–1108
- Harding H. P., Zhang Y., Scheuner D., Chen J. J., Kaufman R. J., Ron D. (2009) **Ppp1r15 gene knockout reveals an essential role for translation initiation factor 2 alpha (eIF2alpha) dephosphorylation in mammalian development** *Proc Natl Acad Sci U S A* **106**:1832–1837
- Hetz C., Axten J. M., Patterson J. B. (2019) **Pharmacological targeting of the unfolded protein response for disease intervention** *Nat Chem Biol* **15**:764–775
- Hoozemans J. J., van Haastert E. S., Nijholt D. A., Rozemuller A. J., Eikelenboom P., Scheper W. (2009) **The unfolded protein response is activated in pretangle neurons in Alzheimer's disease hippocampus** *Am J Pathol* **174**:1241–1251
- Hoozemans J. J., Veerhuis R., Van Haastert E. S., Rozemuller J. M., Baas F., Eikelenboom P., Scheper W. (2005) **The unfolded protein response is activated in Alzheimer's disease** *Acta Neuropathol* **110**:165–172
- Huang F. *et al.* (2020) **Longitudinal biomarkers in amyotrophic lateral sclerosis** *Ann Clin Transl Neurol* **7**:1103–1116
- Ilieva E. V., Ayala V., Jove M., Dalfo E., Cacabelos D., Povedano M., Bellmunt M. J., Ferrer I., Pamplona R., Portero-Otin M. (2007) **Oxidative and endoplasmic reticulum stress interplay in sporadic amyotrophic lateral sclerosis** *Brain* **130**:3111–3123
- Ito Y., Yamada M., Tanaka H., Aida K., Tsuruma K., Shimazawa M., Hozumi I., Inuzuka T., Takahashi H., Hara H. (2009) **Involvement of CHOP, an ER-stress apoptotic mediator, in both human sporadic ALS and ALS model mice** *Neurobiol Dis* **36**:470–476
- Jiang H., Lei R., Ding S. W., Zhu S. (2014) **Skewer: a fast and accurate adapter trimmer for next-generation sequencing paired-end reads** *BMC Bioinformatics* **15**

- Kenner L. R., Anand A. A., Nguyen H. C., Myasnikov A. G., Klose C. J., McGeever L. A., Tsai J. C., Miller-Vedam L. E., Walter P., Frost A. (2019) **eIF2B-catalyzed nucleotide exchange and phosphoregulation by the integrated stress response** *Science* **364**:491–495
- Kernohan K. D. *et al.* (2015) **Homozygous mutation in the eukaryotic translation initiation factor 2alpha phosphatase gene, PPP1R15B, is associated with severe microcephaly, short stature and intellectual disability** *Hum Mol Genet* **24**:6293–6300
- Koentgen F., Lin J., Katidou M., Chang I., Khan M., Watts J., Mombaerts P. (2016) **Exclusive transmission of the embryonic stem cell-derived genome through the mouse germline** *Genesis* **54**:326–333
- Krukowski K. *et al.* (2020) **Small molecule cognitive enhancer reverses age-related memory decline in mice** *Elife* **9**
- Larhammar M. *et al.* (2017) **Dual leucine zipper kinase-dependent PERK activation contributes to neuronal degeneration following insult** *Elife*
- Law C. W., Chen Y., Shi W., Smyth G. K. (2014) **voom: Precision weights unlock linear model analysis tools for RNA-seq read counts** *Genome Biol* **15**
- Liao Y., Smyth G. K., Shi W. (2014) **featureCounts: an efficient general purpose program for assigning sequence reads to genomic features** *Bioinformatics* **30**:923–930
- Lockhart S. M., Saudek V., O’Rahilly S. (2020) **GDF15: A Hormone Conveying Somatic Distress to the Brain** *Endocr Rev* **41**
- Lorenzl S., Albers D. S., LeWitt P. A., Chirichigno J. W., Hilgenberg S. L., Cudkowicz M. E., Beal M. F. (2003) **Tissue inhibitors of matrix metalloproteinases are elevated in cerebrospinal fluid of neurodegenerative diseases** *J Neurol Sci* **207**:71–76
- McGrath E. R. *et al.* (2020) **Growth Differentiation Factor 15 and NT-proBNP as Blood-Based Markers of Vascular Brain Injury and Dementia** *J Am Heart Assoc* **9**
- Nugent A. A. *et al.* (2020) **TREM2 Regulates Microglial Cholesterol Metabolism upon Chronic Phagocytic Challenge** *Neuron* **105**:837–854
- Osipov M. (2022) **Discovery of DNL343: a Potent Selective and Brain-penetrant eIF2B Activator Designed for the Treatment of Neurodegenerative Diseases** *Medicinal Chemistry Gordon Research Conference*
- Pakos-Zebrucka K., Koryga I., Mnich K., Ljujic M., Samali A., Gorman A. M. (2016) **The integrated stress response** *EMBO Rep* **17**:1374–1395
- Phipson B., Lee S., Majewski I. J., Alexander W. S., Smyth G. K. (2016) **Robust Hyperparameter Estimation Protects against Hypervariable Genes and Improves Power to Detect Differential Expression** *Ann Appl Stat* **10**:946–963
- Rabouw H. H., Langereis M. A., Anand A. A., Visser L. J., de Groot R. J., Walter P., van Kuppeveld F. J. M. (2019) **Small molecule ISRIB suppresses the integrated stress response within a defined window of activation** *Proc Natl Acad Sci U S A* **116**:2097–2102
- Robinson M. D., McCarthy D. J., Smyth G. K. (2010) **edgeR: a Bioconductor package for differential expression analysis of digital gene expression data** *Bioinformatics* **26**:139–140

- Robinson M. D., Oshlack A. (2010) **A scaling normalization method for differential expression analysis of RNA-seq data** *Genome Biol* **11**
- Schiffmann R. *et al.* (1994) **Childhood ataxia with diffuse central nervous system hypomyelination** *Ann Neurol* **35**:331–340
- Schoof M., Boone M., Wang L., Lawrence R., Frost A., Walter P. (2021) **eIF2B conformation and assembly state regulate the integrated stress response** *Elife*
- Sidrauski C. *et al.* (2013) **Pharmacological brake-release of mRNA translation enhances cognitive memory** *Elife* **2**
- Skopkova M. *et al.* (2017) **EIF2S3 Mutations Associated with Severe X-Linked Intellectual Disability Syndrome MEHMO** *Hum Mutat* **38**:409–425
- Sonenberg N., Hinnebusch A. G. (2009) **Regulation of translation initiation in eukaryotes: mechanisms and biological targets** *Cell* **136**:731–745
- Storkebaum E., Rosenblum K., Sonenberg N. (2023) **Messenger RNA Translation Defects in Neurodegenerative Diseases. Reply** *N Engl J Med* **388**:2110–2111
- Stutzbach L. D., Xie S. X., Naj A. C., Albin R., Gilman S., Group P. S. P. G. S., Lee V. M., Trojanowski J. Q., Devlin B., Schellenberg G. D. (2013) **The unfolded protein response is activated in disease-affected brain regions in progressive supranuclear palsy and Alzheimer’s disease** *Acta Neuropathol Commun* **1**
- Sun L. D. *et al.* (2023) **The Integrated Stress Response Is Modulated by eIF2B Agonist DNL343: Results From Phase 1 Healthy Subject and Phase 1b ALS Patient Studies** *75th Annual Meeting of the American Academy of Neurology*
- Tsai J. C., Miller-Vedam L. E., Anand A. A., Jaishankar P., Nguyen H. C., Renslo A. R., Frost A., Walter P. (2018) **Structure of the nucleotide exchange factor eIF2B reveals mechanism of memory-enhancing molecule** *Science*
- Unterberger U., Hoftberger R., Gelpi E., Flicker H., Budka H., Voigtlander T. (2006) **Endoplasmic reticulum stress features are prominent in Alzheimer disease but not in prion diseases in vivo** *J Neuropathol Exp Neurol* **65**:348–357
- Uphaus T. *et al.* (2021) **NfL predicts relapse-free progression in a longitudinal multiple sclerosis cohort study** *EBioMedicine* **72**
- van der Knaap M. S. *et al.* (2022) **Therapy Trial Design in Vanishing White Matter: An Expert Consortium Opinion** *Neurol Genet* **8**
- van der Knaap M. S., Pronk J. C., Scheper G. C. (2006) **Vanishing white matter disease** *Lancet Neurol* **5**:413–423
- Vattem K. M., Wek R. C. (2004) **Reinitiation involving upstream ORFs regulates ATF4 mRNA translation in mammalian cells** *Proc Natl Acad Sci U S A* **101**:11269–11274
- Walter P., Ron D. (2011) **The unfolded protein response: from stress pathway to homeostatic regulation** *Science* **334**:1081–1086

Wang C. *et al.* (2018) **Inhibiting the integrated stress response pathway prevents aberrant chondrocyte differentiation thereby alleviating chondrodysplasia** *Elife*

Watkins T. A., Wang B., Huntwork-Rodriguez S., Yang J., Jiang Z., Eastham-Anderson J., Modrusan Z., Kaminker J. S., Tessier-Lavigne M., Lewcock J. W. (2013) **DLK initiates a transcriptional program that couples apoptotic and regenerative responses to axonal injury** *Proc Natl Acad Sci U S A* **110**:4039–4044

Weber A. A., Yang X., Mennillo E., Ding J., Watrous J. D., Jain M., Chen S., Karin M., Tukey R. H. (2022) **Lactational delivery of Triclosan promotes non-alcoholic fatty liver disease in newborn mice** *Nat Commun* **13**

Wethmar K., Smink J. J., Leutz A. (2010) **Upstream open reading frames: molecular switches in (patho)physiology** *Bioessays* **32**:885–893

Wong Y. L. *et al.* (2019) **eIF2B activator prevents neurological defects caused by a chronic integrated stress response** *Elife*

Young S. K., Wek R. C. (2016) **Upstream Open Reading Frames Differentially Regulate Gene-specific Translation in the Integrated Stress Response** *J Biol Chem* **291**:16927–16935

Zyryanova A. F. *et al.* (2018) **Binding of ISRIB reveals a regulatory site in the nucleotide exchange factor eIF2B** *Science* **359**:1533–1536

Article and author information

Ernie Yulyaningsih

Denali Therapeutics, South San Francisco, USA

For correspondence: yulyaningsih@dnli.com

ORCID iD: [0000-0003-2110-2017](https://orcid.org/0000-0003-2110-2017)

Jung H. Suh

Denali Therapeutics, South San Francisco, USA

Melania H. Fanok

Denali Therapeutics, South San Francisco, USA

Roni Chau

Denali Therapeutics, South San Francisco, USA

Hilda Solanoy

Denali Therapeutics, South San Francisco, USA

Ryan Takahashi

Denali Therapeutics, South San Francisco, USA

ORCID iD: [0000-0003-1016-0633](https://orcid.org/0000-0003-1016-0633)

Anna I. Bakardjiev

Denali Therapeutics, South San Francisco, USA

Isabel Becerra

Denali Therapeutics, South San Francisco, USA

N. Butch Benitez

Denali Therapeutics, South San Francisco, USA

Chi-Lu Chiu

Denali Therapeutics, South San Francisco, USA

Sonnet S Davis

Denali Therapeutics, South San Francisco, USA

William E. Dowdle

Denali Therapeutics, South San Francisco, USA, Altos Lab, Redwood City, USA

Timothy Earr

Denali Therapeutics, South San Francisco, USA

Anthony A. Estrada

Denali Therapeutics, South San Francisco, USA

Audrey Gill

Denali Therapeutics, South San Francisco, USA

Connie Ha

Denali Therapeutics, South San Francisco, USA

Patrick C. G. Haddick

Denali Therapeutics, South San Francisco, USA

Kirk R. Henne

Denali Therapeutics, South San Francisco, USA

Martin Larhammar

Denali Therapeutics, South San Francisco, USA, BioArctic, Stockholm, Sweden

ORCID ID: [0000-0002-1547-6760](https://orcid.org/0000-0002-1547-6760)

Amy Wing-Sze Leung

Denali Therapeutics, South San Francisco, USA

Romeo Maciuca

Denali Therapeutics, South San Francisco, USA

Bahram Memarzadeh

Denali Therapeutics, South San Francisco, USA

Hoang N. Nguyen

Denali Therapeutics, South San Francisco, USA

Alicia Nugent

Genentech, South San Francisco, USA

Maksim Osipov

Denali Therapeutics, South San Francisco, USA

Yingqing Ran

Denali Therapeutics, South San Francisco, USA

Kevin Rebadulla

Denali Therapeutics, South San Francisco, USA

Elysia Roche

Denali Therapeutics, South San Francisco, USA

Thomas Sandmann

Denali Therapeutics, South San Francisco, USA

Jing Wang

Denali Therapeutics, South San Francisco, USA, Genentech, South San Francisco, USA

Joseph W. Lewcock

Denali Therapeutics, South San Francisco, USA

ORCID ID: [0000-0003-3012-7881](https://orcid.org/0000-0003-3012-7881)

Kimberly Searce-Levie

Denali Therapeutics, South San Francisco, USA, Cajal Neuroscience, Seattle, USA

Lesley A. Kane

Denali Therapeutics, South San Francisco, USA

Pascal E. Sanchez

Denali Therapeutics, South San Francisco, USA, Altos Lab, Redwood City, USA

Copyright

© 2023, Yulyaningsih et al.

This article is distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use and redistribution provided that the original author and source are credited.

Editors

Reviewing Editor

Hugo Bellen

Baylor College of Medicine, United States of America

Senior Editor

Ma-Li Wong

State University of New York Upstate Medical University, United States of America

Reviewer #1 (Public Review):**Summary:**

In this study, the authors evaluated a novel eIF2B activator, DNL343, in two mouse models representing different forms of the integrated stress response (ISR). They first assessed the pharmacokinetics of DNL343, demonstrating its ability to cross the blood-brain barrier and exhibit good bioavailability. In an acute ISR model induced by optic nerve crush (ONC) injury, DNL343 treatment reduced ISR-induced transcriptional changes and neuronal loss, demonstrating neuroprotective effects. Next, the authors generated an eIF2B loss-of-function mice model by knocking in disease-causing *Eif2b5* variants. The model presents a chronic ISR and mimics vanishing white matter disease (VWMD). DNL343 treatment from the pre-symptomatic stage improved body weight and motor functions corrected transcriptional changes, and reversed proteomic and metabolomic alterations in the brain and cerebrospinal fluid. DNL343 treatment initiated at an advanced disease stage also showed positive effects, restoring body weight gain, suppressing ISR, reducing neurodegeneration biomarkers, and extending lifespan. These findings highlight DNL343 as an effective ISR inhibitor with potential applications in treating VWMD and other neurodegenerative disorders involving ISR.

Strengths:

The study's findings regarding the novel compound DNL343 offer significant promise in addressing VWMD, a condition currently lacking disease-modifying treatment. DNL343 directly targets eIF2B, the disease-causing complex in VWMD, and demonstrates notable efficacy in reversing the integrated stress response (ISR) and mitigating neurodegeneration in a VWMD mouse model. These results raise hope for the potential application of DNL343 in VWMD treatment, a development eagerly anticipated by patients and the VWMD research community. Moreover, the study hints at the broader potential of DNL343 in treating other ISR-related neurodegenerative disorders, such as amyotrophic lateral sclerosis, a prospect that holds broader interest. Additionally, the study's identification of potential biomarkers for VWMD represents a notable strength, potentially leading to improved disease progression assessment pending further confirmation in future research.

Weaknesses:

There are a couple of notable concerns in this study. Firstly, while the *in vivo* evidence strongly supports the efficacy of DNL343 in mitigating ISR and neurodegeneration, there is a lack of direct biochemical evidence to confirm its activity in eIF2B activation. Secondly, the potential for cardiovascular toxicity, which has been reported for a related eIF2B activator in a canine model (as mentioned in the manuscript), has not been evaluated for DNL343 in this study. This data gap regarding toxicity could be crucial for informing the future development of DNL343 for potential human use. Further investigation into these areas would be valuable for a comprehensive understanding of the compound's mechanisms and safety profile.

Reviewer #2 (Public Review):**Summary:**

The authors developed DNL343, a CNS-penetrant small molecule integrated stress response (ISR) inhibitor, to treat neurodegenerative diseases caused by ISR.

Strengths:

DNL343 is an investigational CNS-penetrant small molecule integrated stress response (ISR) inhibitor designed to activate the eukaryotic initiation factor 2B (eIF2B) and suppress aberrant ISR activation. The therapeutic efficacy of DNL343 has been extensively characterized in two animal models. Importantly, plasma biomarkers of neuroinflammation and neurodegeneration can be reversed with DNL343 treatment. Remarkably, several of these biomarkers show differential levels in CSF and plasma from patients with vanishing

white matter disease (VWMD) upon DNL343 treatment. Overall, this is a very exciting study to target ISR for therapeutic interventions.

Weaknesses:

My main questions center around the characterization of DNL343.

1. Is there any biochemical evidence showing DNL343 activates eIF2B, such as binding assays or in vitro biochemical activity assays? A conference presentation was cited - "Osipov, M. (2022). Discovery of DNL343: a Potent Selective and Brain-penetrant eIF2B Activator Designed for the Treatment of Neurodegenerative Diseases. Medicinal Chemistry Gordon Research Conference. New London, NH." However, there needs to be public information about this presentation.
2. How was the selectivity of DNL343 demonstrated? What are the off-targets of DNL343, in particular when DNL343 is administered at a high dose? Thermal-proteasome profiling or photoaffinity labeling experiments could be considered.
3. What are the total drug concentrations in the brain and plasma? What are the unbound ratios?
4. If DNL343 is given intravenously, what are the concentrations in the brain and plasma after 5 minutes and 1 hour or longer time points? In other words, does DNL343 cross BBB through passive diffusion or an active process?
5. What is the complete PK profile of DNL343 for intravenous and oral dosing?
6. Are there any major drug metabolites that could be of concern?

Reviewer #3 (Public Review):

Summary:

ISR contributes to the pathogenesis of multiple neurodegenerative diseases, such as ALS, FTD, VWMD, etc. Targeting ISR is a promising avenue for potential therapeutics. However, previously identified ways to target ISR present some challenges. PERK inhibitors suppress ISR by inhibiting eIF2 α phosphorylation and cause pancreatic toxicity in mice. In order to bypass eIF2 α , previous studies have identified ISR suppressors that target eIF2B, such as ISRIB and 2BAct. These molecules suppress neurodegeneration but do not cause detrimental effects in mouse models. However, ISRIB is water-insoluble, and 2BAct causes cardiovascular complications in dogs, preventing their use in clinics. Here, the authors showed that DNL343, a new ISR inhibitor targeting eIF2B, suppresses neurodegeneration in mouse models. Combined with their previous results of a clinical phase I trial showing the safety of DNL343, these findings suggest the promise of DNL343 as a potential drug for neurodegenerative diseases in which ISR contributes to pathogenesis.

Strengths:

The finding is important and has disease implications, and the conclusion is not surprising.

Weaknesses:

The experimental design and data are hard to comprehend for an audience with a basic research background. This reviewer suggests that the authors use the same way that previous studies on ISRIB and 2BAct (e.g., Wong et al; eLife, 2019) designed experiments and interpret data.